insearchoflastingsolu tionstohiv / aids

Transcription

2 0 0 7
A N N U A L
R E P O R T
I N S E A R C H
S O L U T I O N S
T H E
F O R
F O U N D A T I O N
A I D S
R E S E A R C H
O F
T O
L A S T I N G
H I V / A I D S
a m f A R ,
f o r
T h e
A ID S
R e s e ar c h ,
d e d i c at e d
g l o b a l
F o u n d at i o n
t o
A ID S
t h r o u g h
i s
e n d i n g
t h e
e p i d e m i c
i n n o v at i v e
r e s e ar c h .
Cover photos (from top): TREAT Asia Community Programs Manager Jennifer I-Ching Ho holds an
HIV-positive child (photo: Karl Grobl); Dr. Nolwenn Jouvenet, Aaron Diamond AIDS Research Center
(photo: Dr. Rowena Johnston); Shan Grant, Miguel Rivera, and Robert Green (photo: Winnie McCroy).
FROM THE CHAIRMAN
A Global Force Against a Global Epidemic
FROM THE CHIEF EXECUTIVE OFFICER
Good Research Drives Good Policy
02
03
PEOPLE LIVING WITH HIV/AIDS
04
MAJOR ACCOMPLISHMENTS
06
RESEARCH
08
GLOBAL INITIATIVES
15
PUBLIC POLICY
22
EDUCATION AND INFORMATION
GIVING
Individual Giving
Institutional Giving In-Kind Contributions
Planned Giving
Volunteer Support
Workplace Giving
FINANCIAL SUMMARY
From the Treasurer and the Chair of the
Finance and Budget Committee
Statement of Activities and Changes in Net Assets
Statement of Financial Position
LEADERSHIP AND ADVISORY COMMITTEES
ACKNOWLEDGMENTS
26
30
44
46
f r o m
t h e
C h a i r m a n
A Global Force Against a Global EPIDEMIC
Of the 33 million people living with HIV/AIDS, more than 90 percent are in the developing world. For most of its 23 years at the leading edge of the fight against AIDS, amfAR
has brought AIDS research, prevention, and education to countries hard hit by the
epidemic. A global health threat demands nothing less than a global response. A couple
of years ago, we changed our name from the American Foundation for AIDS Research to
The Foundation for AIDS Research to reflect the increasingly international scope of both
the epidemic and amfAR’s work.
The TREAT Asia Network that amfAR formed in 2001 is now a highly regarded model
of regional collaboration on HIV/AIDS research, education, and training across Asia and
the Pacific. In 2007 we launched an important new international venture: the MSM
amfAR Annual Report 2007
02
Initiative. The first round of community awards that form the core of this initiative will
support front-line organizations working to combat the rapid and deadly spread of HIV
among men who have sex with men (MSM) in Africa, the Caribbean, and Southeast Asia.
In 2008, additional awards will be made for innovative programs in Latin America and
Asia and the Pacific.
Here in the U.S., some of our own cities have rates of infection that rival parts of
the developing world. In Washington, D.C., one in 20 residents is HIV positive. So we
continue to fight for evidence-based policies that are essential to reducing infection rates
and for adequate levels of government funding for HIV/AIDS research, treatment, and
From the Chairman
prevention.
The international growth of amfAR’s programs has been matched by a corresponding expansion in the fundraising arena. For many years, our successful Cinema Against
AIDS series has raised funds and brought AIDS awareness to a global audience during
the Cannes International Film Festival. In 2007 we were invited to bring the event to
the Rome and Dubai film festivals. These new venues enable us to teach new audiences
about the vital importance of AIDS research and to combat HIV-related stigma.
Our fundraising efforts will be greatly assisted by the passion and dedication of
Sharon Stone, who has taken on the role of global fundraising chairman. On the staff
side, we are pleased that Kevin Frost, who ably served for many years as vice president
for global initiatives, has accepted the position of chief executive officer. Kevin’s experience, energy, and vision will help guide and drive amfAR as we expand our international
initiatives while maintaining our fundamental commitment to AIDS research.
As we embrace the challenges that confront us, we recognize that our work and
accomplishments would not be possible without the continued support of generous
individuals and organizations. Your ongoing commitment inspires us and enables us
to quicken the pace of our efforts to end this deadly epidemic.
Kenneth Cole
Chairman of the Board
f r o m
t h e
C h IEF
E X E C U TI V E
OFFI C ER
Good R esearch D rives Good P olicy
I like to think that amfAR has the mind of a scientist and the soul of an activist. For 23
years, we have pushed at the frontiers of AIDS research, investing in unexplored areas
that have yielded new treatments, improved prevention methods, and vital clues to HIV
eradication. And we have pushed for AIDS-related policies rooted in science, compassion, and common sense.
Both advocacy and research require patience and persistence, and can take years
to bear fruit. Studies that amfAR funded in 1995, for example, pointed the way to the
to patients developing resistance to currently available treatments.
While past amfAR grants and fellowships continue to influence the discoveries of
today, we launched a new initiative in 2007 that will help shore up the future of AIDS
research. Young scientists are often those with the most ingenious ideas, but increasingly fierce competition for funds threatens to drive them away from research on AIDS.
Our Mathilde Krim Fellowships in Basic Biomedical Research provide a critical source of
funds that will help nurture these AIDS research leaders of tomorrow.
While substantial resources are quite rightly being invested in the delivery of treatment to those who need it, there is a growing consensus that insufficient attention
is being paid to research. That consensus was enshrined in the Sydney Declaration of
2007, which recommends that 10 percent of all HIV/AIDS funding be devoted to
research. amfAR was among almost 2,000 signatories of the Declaration, which stressed
that the necessary research should extend well beyond the laboratory. Basic science is
essential, of course, but above all, research is about people, communities, and human
behavior.
As the Sydney Declaration states, “good research drives good policy.” We couldn’t
agree more, since it is good policy that delivers the benefits of research to people. As
scientists and activists, we shall continue to support the best AIDS research and the
smartest AIDS policies until we bring this deadly epidemic to an end.
Kevin Robert Frost
Chief Executive Officer
03
From the Chief Executive Officer
drugs. These so-called CCR5 blockers bring an important new option—and new hope—
development and approval in 2007 of the first medication in a brand new class of AIDS
PEOPLE LIVING WITH HIV/AIDS, 2007
North America
1.3 million
(480,000–1.9 million)
04
People Living With HIV/AIDS
Caribbean
230,000
(210,000–270,000)
World at a Glance
• 33.2 million people were
living with HIV/AIDS in 2007.
• 2.1 million of them were
under the age of 15.
• 2.5 million people were
estimated to be infected
with HIV in 2007.
• 420,000 were under the
age of 15.
• 6,800 people contract HIV
every day—283 every hour.
• 2.1 million people died
from AIDS in 2007.
• 290,000 of them were
under the age of 15.
Source:
Source: UNAIDS
UNAIDS/World Health Organization
Latin America
1.6 million
(1.4–1.9 million)
Global Total: 33.2 million
Western &
Central Europe
760,000
Eastern Europe &
Central Asia
1.6 million
(1.2–2.1 million)
(600,000–1.1 million)
East Asia
800,000
(620,000–960,000)
(3.3–5.1 million)
(270,000–500,000)
Sub-Saharan Africa
22.5 million
(20.9–24.3 million)
Oceania
75,000
(53,000–120,000)
The numbers indicated in parentheses define the boundaries within which
the actual numbers lie, based on the best available information.
05
People Living With HIV/AIDS
North Africa &
Middle East
380,000
South &
Southeast Asia
4 million
(30.6–36.1 million)
M a j o r
A C C OM P L I S HMENT S ,
2 0 0 7
Securing the Future of AIDS Research
Advocacy Efforts Pay Off
Funding sources for promising young scientists have become
amfAR has been a leading advocate of the increased federal
increasingly difficult to secure, yet these same young research-
funding for AIDS research that is necessary to continue U.S.
ers are often those with the most innovative ideas. To support
leadership in cutting-edge discoveries related to the preven-
these future leaders of AIDS research and to advance their
tion, care, and treatment of HIV/AIDS. The Foundation’s efforts
promising studies, in 2007 amfAR launched the Mathilde Krim
contributed to a $619.5 million increase in the FY 2007 budget
Fellowships in Basic Biomedical Research. Named for amfAR’s
of the National Institutes of Health and an additional $330
founding chairman, the
Krim Fellowships moved
from concept to funding in
06
million increase in FY 2008.
Syringe Exchange Funding Ban Overturned
Major Accomplishments
less than a year.
In Washington, D.C., where one in 20 residents is living with
New HIV/AIDS
Drug Class
Gains Approval
local taxpayer dollars to fund syringe exchange programs—
In August, the Food and
exchange in the District and has been vocal and persistent in
Drug Administration
its opposition to the ban. In 2007, both the House and Senate
approved maraviroc, the
finally removed the restrictive legislative language, an advocacy
first in a new class of anti-
triumph that was a decade in the making.
HIV, the federal government long banned the city from using
a proven approach to HIV prevention. Since the ban was
imposed, amfAR has provided grants to support syringe
HIV drugs called CCR5blockers. amfAR played
a major role in spurring
Stemming the Tide of AIDS Among Men
Who Have Sex with Men
the early development of maraviroc through initial research
Recent studies show surging rates of HIV infection among men
by amfAR grantee Dr. Nathaniel Landau, who first described
who have sex
the vital role of CCR5 in HIV infection and the likelihood that
with men (MSM)
blocking it would not be detrimental to human health. A study
in resource-limited
showed that by simply adding maraviroc to existing combina-
countries, where
tion antiretroviral therapy, patients are twice as likely to attain
discrimination
undetectable virus levels.
and denial of
male-male sex
Cutting-Edge Grants and Fellowships
continue to fuel
In 2007, amfAR awarded 18 research grants and fellowships
the epidemic.
in two cycles totaling more than $2.1 million. One round of
In an effort to
awards supported a range of projects aimed at increasing
bolster prevention and treatment efforts and to combat stigma,
understanding and prevention of rectal HIV transmission; the
amfAR launched the MSM Initiative. The cornerstone of the
second focused on research that would increase understanding
Initiative is a community awards program that will funnel
of the social and biological factors that influence, or undermine,
urgently needed resources to grassroots groups in developing
the effective treatment of HIV/AIDS.
countries in support of their innovative HIV/AIDS programs that
build on and extend the benefits of current research.
Saving the Lives of Children in Asia
funded investigators were published in leading peer-reviewed
Close to 200,000 children are living with HIV/AIDS in Asia
journals. These reports and their dissemination among the
and it is estimated that only 20 percent of them are receiv-
scientific community are essential for researchers to fit together
ing the treatment and care they so desperately need. To help
the pieces of the intricate AIDS puzzle.
Educating Healthcare Providers
amfAR’s TREAT Asia
amfAR is one of a small group of AIDS organizations accredited
Network launched a
to provide continuing medical education to physicians and
pediatrics initiative in
other healthcare providers. In 2007, the Foundation presented
2006. The initiative
a continuing medical education series in 10 U.S. cities address-
involves 22 pediatric
ing the needs of treatment-experienced patients. The series
clinics, hospitals, and
reached more than 550 health-
research centers across
care professionals, primarily
Asia that are working
nurse practitioners and physician
collaboratively on HIV
assistants with heavy HIV case
treatment and clinical
loads. Two community forums
research. A pediatric
on antiretroviral therapy were
HIV observational
also conducted, along with eight
database, established
think tanks that examined gaps
in 2007, is now pooling patient information that will help
in HIV/AIDS education in the U.S.
researchers find urgently needed answers to the optimal treat-
and ways to fill them.
ment of pediatric HIV.
Giant Steps for MSM in Asia
Charting the Worldwide
Course of AIDS
HIV infection rates are disproportionately high among MSM in
In an effort to create a global database large enough to
many parts of Asia. To fight collectively for regional HIV preven-
address detailed questions about the worldwide course of HIV/
tion and treatment services for this long-ignored population, a
AIDS, U.S. health authorities established an ambitious interna-
consortium of more than 80 grassroots HIV organizations has
tional collaboration known as the International Epidemiologic
come together as the Purple Sky Network. Its activities across
Databases to Evaluate AIDS. TREAT Asia was selected to
a large swath of Southeast Asia are coordinated by TREAT Asia.
manage the Asia/Pacific section of this project, which began its
Thanks in part to the efforts of the Purple Sky Network, five out
first year of operation in 2006.
of the six countries in the Mekong region have adopted specific
plans that address the HIV/AIDS needs of MSM.
Tracking the Spread of Drug-Resistant HIV
HIV drug resistance is perhaps the single greatest factor
Expanding the HIV Knowledge Base
influencing the long-term success of treatment scale-up efforts
amfAR-funded research continues to generate a steady stream
in Asia. In 2007, TREAT Asia began enrolling clinical studies
of important new knowledge about HIV/AIDS. In 2007, more
to monitor the development of HIV drug resistance in Asia.
than 40 scientific papers authored or co-authored by amfAR-
These studies will help to develop capacity for monitoring and
surveillance of the spread of drug-resistant HIV in developing
countries.
07
Major Accomplishments
life for these children,
improve and extend
M
RE S EAR C H
illions of people
with HIV/AIDS are living longer, healthier lives as a direct result of AIDS research. The
powerful anti-HIV drugs that are increasingly finding their way to even the most far-flung
populations all had their genesis in the laboratory. Three of the AIDS drug classes in use
today have their origins in amfAR-funded research.
Similarly, AIDS research has helped prevent countless new HIV infections. In many
parts of the developed world, for example, mother-to-child transmission of HIV has been
all but eliminated. This is in large part due to the use of antiretroviral drugs to block
mother-to-child transmission, a concept pioneered by amfAR-supported research in the
early days of the epidemic.
Today, amfAR continues to support pioneering studies in
areas that are not being adequately investigated by others.
the timing of their establishment, in order to understand how
potential cures must work.
Working on the frontiers of AIDS research, amfAR-funded
scientists are attacking HIV from numerous angles. amfAR’s
New AIDS Drug Has Roots in amfAR Research
research strategy can be divided into three objectives:
In 2007, the first in a new class of anti-HIV drugs became
available to patients who are not responding to other AIDS
• Ensuring that all people living with HIV reap the benefits of
medications. Approved by the FDA in August, maraviroc acts
by blocking HIV’s access to the CCR5 protein on the surface of
susceptible cells. A study of more than 600 patients showed
that adding maraviroc to combination antiretroviral therapy
• Searching for lasting solutions leading to an AIDS-free
was twice as likely to result in undetectable virus levels. It was
amfAR grantee Dr. Nathaniel Landau and others who, in the
future.
Spreading the Benefits of AIDS Research:
Optimizing Treatment
Not everyone has benefited equally from the enormous
advances in HIV/AIDS treatment of recent years. Biological
factors can influence responses to treatment, while social
circumstances can hinder access to HIV testing and medical
care. In June 2007, amfAR granted nearly $1.2 million for
10 studies aimed at gaining a better understanding of these
impediments to optimal HIV treatment and care.
Grantee Dr. Jennifer Sayles of the University of California,
Los Angeles, is studying the validity of a new measure of HIV-
1990s, identified the key role of CCR5 in HIV infection and
illuminated a path to developing a new drug class.
amfAR grantee Dr. Nancy Shulman of Stanford University
and Palo Alto V.A. Medical Center has explored whether maraviroc can also decrease the activation of the immune system,
which may also help prevent disease. She said of her research,
“If maraviroc can decrease HIV disease both by blocking HIV
entry into cells as well as decreasing immune activation, this
could have implications for broadening the use of maraviroc—
even in patients who might otherwise seem to be unsuitable
candidates for the drug.”
related stigma in women, with the long-term goal of identifying factors that might guide future interventions to improve
the quality of women’s healthcare. The number of women
living with HIV is increasing, and around the world, women
face stigma and even violence because of their HIV status. The
U.S. is no exception, according to a survey conducted by Harris
Interactive for amfAR in 2007 (see page 29). Reducing stigma
would dismantle a pervasive barrier to HIV testing, treatment,
and care.
Three of the new studies will assess the implications of
changes in HIV testing recommendations adopted by the
Centers for Disease Control and Prevention (CDC) in 2007. In
the face of stubbornly high infection rates in the U.S., the CDC
now advises healthcare professionals to perform routine HIV
screening of adults, adolescents, and pregnant women.
Other researchers will examine the influence of biologi-
cal factors on treatment patterns. Dr. Stephen Kent of the
University of Melbourne, Australia, is studying HIV reservoirs,
where the virus persists beyond the reach of the immune
system or antiretroviral therapy. He is examining the nature of
the virus strains that become part of these reservoirs, as well as
“Twenty-five years after the
first identification of AIDS,
the taboos that surround an
open discussion of sexual
behavior are still haunting
us in our efforts to contain
this pandemic. It is time for
us to take an honest and unflinching look at how HIV is
spread and how to minimize
the risks.”
particularly in the area of HIV prevention; and
09
Research
past research accomplishments;
• Addressing the current needs of vulnerable populations,
The Krim Fellowships are a
fitting tribute to the vision
and unwavering commitment
to research of amfAR
Founding Chairman
Dr. Mathilde Krim.
10
Research
I
Rejuvenating the Field of AIDS Research
“The Krim Fellowships
are an excellent
example of how
amfAR facilitates
the entry of young
scientists into the
field of AIDS research.
They’ll be the leaders
of tomorrow.”
n January 2007, amfAR launched a new research initiative in
honor of its founding chairman: The Mathilde Krim Fellowships
in Basic Biomedical Research. The aim was to confront an urgent
problem. At a time when HIV/AIDS kills more than 2 million
people each year, it has become increasingly difficult for bright
young scientists to secure funding for their innovative research
projects.
The proportion of funding awarded to scientists aged 35 or younger has
declined steadily from 23 percent in 1980 to below four percent in 2001,
according to a study by the National Institutes of Health. Meanwhile, the
share of grants going to older scientists has increased sharply. The result is
that young scientists, looking for support for original ideas, are increasingly
forced to leave academia.
Addressing this gap and moving from concept to funding in less than a
year, the Krim Fellowships are designed to support bright young scientists’
biomedical research aimed at treating, preventing, and eradicating HIV/AIDS.
The program funds two years of postdoctoral research, with the possibility of
one additional year of research support during the first year in a tenure-track
position.
The first round of applications for the Krim Fellowships was reviewed
in the fall of 2007. “We received many applications of extraordinarily high
caliber from leading laboratories around the world,” said Dr. Rowena
Johnston, amfAR’s vice president of research. “The overwhelming response
to this program underscores the pressing funding needs of new researchers
as support has dried up from other sources.”
“The Krim Fellowships are an excellent example of how amfAR facilitates
the entry of young scientists into the field of AIDS research,” said Dr. Paul
Bieniasz of the Aaron Diamond AIDS Research Center in New York. “They’ll
be the leaders of tomorrow.”
Understanding Rectal HIV
Transmission
“Twenty-five years after the first identification
of AIDS, the taboos that surround an open
discussion of sexual behavior are still haunting
us in our efforts to contain this pandemic,” said
Dr. Rowena Johnston, amfAR’s vice president for
research. “It is time for us to take an honest and
unflinching look at how HIV is spread and how
to minimize the risks.”
Up until now, there have been few studies
of the extent to which HIV is spread by anal
intercourse—a gap in knowledge that has left
both men and women vulnerable to infection.
Increased understanding of rectal transmission
will play an important role in developing strategies to reach people who have previously been
overlooked in HIV prevention. In January 2007,
amfAR awarded eight grants and fellowships totaling nearly $1 million for research that tackles
both the biological and social aspects of rectal
transmission in order to remove the barriers to
understanding and preventing this widespread
mode of transmission.
Toward a Cure
The development of highly active antiretroviral
therapy (HAART), which has extended and
improved the lives of many people living with HIV, has been
“elite controllers” may provide insight into slowing or even
hailed as one of the great scientific achievements of the last
stopping viral reproduction.
Expanding the HIV Knowledge Base
the burden of taking medications—which can cause debilitat-
An important indicator of the caliber and productivity of
ing side effects—for the rest of their lives.
amfAR-supported researchers is the quantity of studies
published in peer-reviewed journals. In fiscal year 2007, more
amfAR-funded scientists are rising to the challenge. A
number of researchers who received grants under amfAR’s viral
than 40 papers by amfAR grantees and fellows appeared in
eradication initiative continued their important work in 2007,
the scientific press, contributing a wealth of important new
exploring potential methods of flushing out latent virus that is
knowledge about HIV that can be exploited by the broader
hidden beyond the reach of current antiretroviral therapy.
research community.
• amfAR fellow Dr. Fedde Groot is studying the ways in which
Defining Drug Targets
HIV targets uninfected cells in the gastrointestinal (GI) tract
Dr. Jacqueline Reeves of Monogram Biosciences and Dr. Oliver
and how virus spread can be controlled by drugs or antibodies.
Hartley of the University of Geneva studied the process of
Since the degree of cell loss in the gastrointestinal tract may
mutation by which HIV is able to evade containment by current
largely determine the course of the disease, Dr. Groot’s findings
drug therapies. There are two varieties of co-receptor that HIV
may guide future efforts to reduce or prevent cell loss.
uses to bind to a cell: CCR5 and CXCR4. CCR5 is the portal
• In a similar vein, Dr. Martin Markowitz and his team at the
that HIV uses in nearly all cases of initial HIV infection. But
Aaron Diamond AIDS Research Center are exploring potential
over time, particularly in the absence of anti-HIV treatment, the
viral reservoirs in the GI tract, and have found that T-cell levels
virus often evolves into a form that can use CXCR4. And this
in the intestinal tract remained below normal despite treat-
mutated version usually signals a much more virulent disease.
ment. These study results will help guide interventions aimed at
Drs. Reeves, Hartley, and colleagues identified the intermediate
preventing the loss of, or replenishing, immune cells in the GI
steps the virus progresses through in the switch from using
tract, which are killed early in infection.
CCR5 to CXCR4. Their research, published in the Journal of
• Dr. Steven Deeks of the University of California, San Fran-
Virology, will help determine both the potential and the limita-
cisco, is examining HIV-positive people whose immune systems
tions of anti-HIV drugs that target the CCR5 co-receptor.
have controlled the virus without treatment. Studying these
Another amfAR grantee, Dr. Pantelis Poumbourios of the
Working with a group of amfAR-funded researchers in Australia, Dr. Ya-Lin Chiu
identified a new group of immune cells that harbor HIV.
11
Research
virus from the body completely, and to free HIV patients from
25 years. But the ultimate goal is to find ways to eradicate the
Burnet Institute in Victoria, Australia, described in the Journal of
capitalize on recent research findings and emerging areas of
Biological Chemistry his exploration of HIV-cell fusion, a process
study. In addition to one-year grants for senior researchers,
targeted by one of the newest anti-HIV drugs, Fuzeon
the Foundation funds two-year fellowships for postdoctoral
(enfuvirtide). The new knowledge gained by Dr. Poumbourios
scientists working with an established mentor. The Founda-
and his research group may facilitate the discovery of new
tion’s support of early-stage and sometimes high-risk projects
drugs to block the fusion process, and thus the formation of
is a proven investment: for every dollar scientists receive from
infectious virus.
amfAR, they receive an average of $12 in subsequent funding
from other sources.
Identifying Roadblocks to a Cure
Melbourne, Australia, worked with amfAR fellows Dr. Ya-Lin
A Relentless Pursuit of Prevention, Treatment,
and Cure
Chiu and Dr. Secondo Sonza to identify a new group of immune
In the months and years ahead, amfAR will continue to make
cells that harbor HIV. They found that, in addition to CD4+
judicious investments in the research that is essential for the
cells, a small subset of immune cells known as monocytes also
ultimate conquest of AIDS. Preventing all new HIV infections
harbor HIV during HAART. The group found that these cells
calls for contributions from every area of HIV/AIDS research.
may represent a continuing source of viral persistence, even
Progress towards designing an AIDS vaccine or microbicide,
in individuals with viral loads suppressed below detectable
for example, is being made by biomedical researchers, while
limits for prolonged periods of time, and could therefore limit
social and behavioral scientists seek to understand the social
the potential for a cure. Their findings, which appeared in the
and psychological factors that can affect the adoption of HIV
Journal of Immunology, support the necessity of pursuing all
prevention and risk reduction behaviors. Unlike other funders
12
possible concepts for curing HIV/AIDS, for people at all stages
of HIV/AIDS research, amfAR aims to integrate these facets of
of the disease.
research in the drive to ensure not only that new prevention
amfAR grantee Dr. Suzanne Crowe of the Burnet Institute in
Research
and treatment interventions are discovered but also that they
Minor HIV Genes
are successfully put into practice.
The amfAR-funded lab of Dr. Nathaniel Landau and amfAR-
supported fellow Dr. Lei Fang researched two accessory or
the inexorable spread of drug-resistant strains of HIV demand
“minor” genes of HIV, Vif and Vpr. Writing in Virology and
the continual pursuit of new treatments. amfAR-funded
Proceedings of the National Academy of Sciences, the research team
scientists will continue to search for new angles from which
described their work, which could point the way to new targets
to attack the virus. Our brightest hope for the future, however,
for anti-HIV drug development.
lies in understanding the mechanisms by which HIV evades not
The often debilitating side effects of current AIDS drugs and
only the vigorous immune response mounted by those who
HIV and the Brain
amfAR-funded scientist Dr. Beau Ances studied the changes
in mental function associated with HIV infection and the
impact of HAART on cognitive function. Despite a decline in
the incidence of HIV-related dementia due to increased use of
HAART, it appears that some patients still experience cognitive
problems. Writing in Archives of Neurology, Dr. Ances and his
team described the new, more sensitive test they created to
measure HIV’s effects on the brain.
Securing the Future of AIDS Research
With the help of its Scientific Advisory Committee and other
independent HIV/AIDS experts who volunteer to take part in
the peer-review selection process, amfAR moves quickly to
are infected, but also the very potent drugs that constitute the
current arsenal of anti-HIV therapy. A clearer understanding of
these mechanisms will help create the roadmap to a cure.
October 1, 2006, to September 30, 2007. Grants funded during fiscal
year 2007 but awarded in previous years are shown with the year of
the award in parentheses.
Research Grants
Preventing HIV Transmission
Development of a standard rectal
microbicide delivery device
Alex Carballo-Diéguez, Ph.D.
Research Foundation for Mental
Hygiene, Inc.
New York, NY
$119,992
Colorectal explants to study HIV
transmission and microbicides
Charlene Dezzutti, Ph.D.
Magee-Womens Research Institute
and Foundation
Pittsburgh, PA
$120,000
HIV-1 infection of mucosal
lymphocytes and tissue explants
Benjamin K. Chen, M.D., Ph.D.
Mount Sinai School of Medicine
New York, NY
$90,000 (2006)
Interaction of HIV with the macaque
female genital tract
Thomas J. Hope, Ph.D.
Northwestern University
Chicago, IL
$90,000 (2006)
Viral transmission and replicative
fitness
Dale McPhee, Ph.D.
St Vincent’s Institute
Fitzroy, Australia
$90,000 (2006)
Epithelial injury and HIV penetration
after simulated ejaculation
Craig Hendrix, M.D.
Johns Hopkins University School of
Medicine
Baltimore, MD
$120,000
Female genital ulcer as a portal of
HIV entry
Eva Rakasz, Ph.D.
University of Wisconsin–Madison
Madison, WI
$90,000 (2006)
Mediation effect of network function
on HIV risk behavior among Chinese
Hongjie Liu, Ph.D.
School of Medicine, Virginia
Commonwealth University
Richmond, VA
$119,988
Understanding the properties of
transmitted HIV-1 variants
Manish Sagar, M.D.
Brigham and Women’s Hospital/
Harvard Medical School
Boston, MA
$90,000 (2006)
Anal sex practices in high-risk South
African women and men
Joanne Mantell, Ph.D.
Hygiene, Inc.
New York, NY
$119,946
Amphibian derived microbicides that
inhibit HIV infection
Derya Unutmaz, M.D.
Vanderbilt University Medical School
Nashville, TN
$90,000 (2005)
Rectal transmission of HIV-1 in a novel
mouse model
Roberto Speck, M.D.
Division of Infectious Diseases,
Department of Internal Medicine,
University Hospital of Zurich
Zurich, Switzerland
$119,822
Optimizing HIV Treatment
Recent changes in HIV testing recommendations: impact on youth at risk
Marya Gwadz, Ph.D.
NDRI USA, Inc.
New York, NY
$119,598
Vif:APOBEC3G: assay and structure
Nathaniel Landau, Ph.D.
Salk Institute for Biological Studies
La Jolla, CA
$90,000 (2004)
Antibody mimetic inhibitors
of HIV fusion
Richard Roberts, Ph.D.
California Institute of Technology
Pasadena, CA
$86,302 (2004)
Establishment of the HIV reservoir
during acute infection
Stephen Kent, M.D.
University of Melbourne
Melbourne, Australia
$120,000
Pursuing HIV Eradication
How to test: policy and practice after
the CDC recommendations
Lori Leonard, Sc.D.
Johns Hopkins School of Public Health
Baltimore, MD
$120,000
Genetic screens for inhibitors of HIV
latency
Paul Bieniasz, Ph.D.
Aaron Diamond AIDS Research Center
New York, NY
$120,000 (2006)
CDC HIV testing guidelines: unresolved
ethical concerns
Roland Merchant, M.D., Sc.D.
Rhode Island Hospital
Providence, RI
$120,000
HIV controllers: a potential model for
HIV eradication
Steven Deeks, M.D.
University of California, San Francisco
San Francisco, CA
$120,000 (2006)
AHI awareness and entry into care
among high risk populations
Robert Remien, Ph.D.
Hygiene, Inc.
New York, NY
$119,654
The role of CCR7 ligands and dendritic
cells in latent HIV infection
Sharon Lewin, F.R.A.C.P., Ph.D.
Monash University
$120,000 (2006)
The impact of stigma on access to HIV
treatment and care
Jennifer Sayles, M.D.
University of California, Los Angeles,
David Geffen School of Medicine
Los Angeles, CA
$120,000
Immunologic benefits of CCR5
inhibitor intensification
Nancy Shulman, M.D.
Palo Alto Veterans Administration
Medical Center and
Stanford University
Palo Alto, California
$107,644
Evolutionary screen to identify novel
TRIM restriction factors
Harmit Malik, Ph.D.
Fred Hutchinson Cancer Research
Center
Seattle, WA
$90,000 (2005)
Reservoirs of SIV in long-term
nonprogressors in rhesus macaques
Binhua Ling, M.D., Ph.D.
Tulane National Primate Research
Center
Covington, LA
$120,000 (2006)
The GI tract may be a reservoir of
ongoing viral replication during HAART
Martin Markowitz, M.D.
Aaron Diamond AIDS Research Center
New York, NY
$120,000 (2006)
Role of lymph node dendritic cells in
HIV infection
David McDonald, Ph.D.
Case Western Reserve University
Cleveland, OH
$120,000 (2006)
Identifying the major tissue reservoirs
in SIV/SHIV infected macaques
Bapi Pahar, Ph.D.
Tulane National Primate Research
Center
Covington, LA
$120,000 (2006)
All projects listed below were supported by amfAR during the period
Impact of PD-1 on the establishment and maintenance of the HIV-1
reservoir
Elias Haddad, Ph.D.
Université de Montréal, Centre de
Recherche du CHUM
Montréal, Canada
$107,568
13
Research
2007 RESEARCH GRANTS AND AWARDS
Effects of valproic acid therapy on gut
mucosal HIV reservoirs
Jean-Pierre Routy, M.D.
McGill University Health Centre
Montréal, Canada
$119,827 (2006)
Viral persistance in the MGT of RTSHIV infected macaques on HAART
Miranda Xhilaga, Ph.D.
Mentor: Sharon Lewin, F.R.A.C.P., Ph.D.
Monash University
$125,000
Research Fellowships
Molecular mechanisms of the HIV-1
coreceptor CCR5 function
Gabriel Birrane, Ph.D.
Mentor: John Ladias, M.D.
Beth Israel Deaconess Medical Center
Boston, MA
$99,000 (2006)
Preventing HIV Transmission
14
Colorectal responses to HIV-1 and
modulation by microbicides
Carolina Herrera, Ph.D.
Mentor: Robin Shattock, Ph.D.
St George’s University of London
London, United Kingdom
$125,000
Anal intercourse, STIs and HIV among
STD clinic clients
Marjan Javanbakht, Ph.D.
Mentor: Peter Anton, M.D.
University of California, Los Angeles
Los Angeles, CA
$112,193
Research
HIV mucosal transmission in
humanized mice model
Liguo Zhang, Ph.D.
Mentor: Lishan Su, Ph.D.
University of North Carolina at
Chapel Hill
Chapel Hill, NC
$99,000 (2006)
Harnessing RNA interference as an
HIV microbicide
Deborah Palliser, Ph.D.
Mentor: Judy Lieberman, M.D., Ph.D.
CBR Institute for Biomedical Research
Boston, MA
$99,000 (2005)
Structure based design of gp41
analogs for HIV1 vaccines
Florence Brunel, Ph.D.
Mentor: Philip Dawson, Ph.D.
Scripps Research Institute
La Jolla, CA
$99,000 (2004)
Optimizing HIV Treatment
Impulsivity, drug abuse, and HIV
medication adherence: An fMRI study
Christina Meade, Ph.D.
Mentor: Steven Safren, Ph.D.
Harvard Medical School–McLean
Hospital/Massachusetts General
Hospital
Belmont, MA
$124,000
Designing inducible Pol II systems for
RNA interference of HIV-1
Hoshang Unwalla, Ph.D.
Mentor: John Rossi, Ph.D.
Beckman Research Institute of the City
of Hope
Duarte, CA
$99,000 (2006)
The APOBEC3G-Vif interaction as a
new HIV therapeutic target
Hendrik Huthoff, Ph.D.
Mentor: Michael Malim, D.Phil.
King’s College London
London, United Kingdom
$99,000 (2005)
Mechanistic study of retroviral entry
and restriction in vitro
Virginie Sandrin, Ph.D.
Mentor: Wesley Sundquist, Ph.D.
University of Utah
Salt Lake City, UT
$99,000 (2005)
Mechanism of postentry restriction of
HIV-1 by TRIM5alpha
Chisu Song, Ph.D.
Mentor: Christopher Aiken, Ph.D.
Vanderbilt University School of
Medicine
Nashville, TN
$99,000 (2005)
Negative regulation of HIV-1 cellular
co-factor P-TEFb
Matjaz Barboric, Ph.D.
Mentor: Matija Peterlin, M.D.
San Francisco, CA
$99,000 (2004)
HIV-1 envelope-gag interactions and
assembly in lipid rafts
Jayanta Bhattacharya, Ph.D.
Mentor: Ramesh Paranjape, Ph.D.
National AIDS Research Institute
Pune, India
$9,000 (2004)
Relative fitness of early and late
variants of SIV in vitro
Yegor Voronin, Ph.D.
Mentor: Michael Emermann, Ph.D.
Fred Hutchinson Cancer Research
Center
Seattle, WA
$99,000 (2004)
Pursuing HIV Eradication
Quantitative fMRI of CNS-T ART on
HIV brain reservoirs
Beau Ances, M.D., Ph.D.
Mentor: Ronald Ellis, M.D., Ph.D.
University of California San Diego
San Diego, CA
$125,000 (2006)
HIV-1 cell-cell spread in viral
dissemination and persistence
Fedde Groot, M.Sc.
Mentor: Quentin Sattentau, Ph.D.
The Sir William Dunn School of
Pathology, University of Oxford
Oxford, United Kingdom
$124,882 (2006)
Virologic correlates of subtype-A HIV
transmission
Richard Haaland, Ph.D.
Mentor: Eric Hunter, Ph.D.
Emory University
Atlanta, GA
$99,000 (2006)
Role of Tat methylation in HIV latency
Sara Pagans, Ph.D.
Mentor: Melanie Ott, M.D.
The J. David Gladstone Institutes
San Francisco, CA
$125,000 (2006)
Macrophage matrix metalloproteinases role in persistence of HIV-1 in
CNS
Nicole Webster, Ph.D.
Mentor: Suzanne Crowe, M.D.
Macfarlane Burnet Institute for
Medical Research and Public Health
$125,000 (2006)
HIV reservoir in central memory T cells
Nicolas Chomont, Ph.D.
Mentor: Rafick-Pierre Sekaly, Ph.D.
Université de Montréal
Centre de Recherches du CHUM
Montréal, Canada
$83,100 (2005)
Identification of novel host factors
for HIV replication
Lei Fang, M.D., Ph.D.
Mentor: Nathaniel Landau, Ph.D.
The Salk Institute for Biological
Studies
La Jolla, CA
$99,000 (2005)
Characterization of HIV env variants
that persist during HAART
Patrick Harrington, Ph.D.
Mentor: Ronald Swanstrom, Ph.D.
University of North Carolina at
Chapel Hill
Chapel Hill, NC
$99,000 (2005)
Kinetics of HIV reactivation in latently
infected T cells
Young Kyeung Kim, Ph.D.
Mentor: Jonathan Karn, Ph.D.
Case Western Reserve University
Cleveland, OH
$99,000 (2005)
Human cellular factors that restrict
HIV infection
Susana Valente, Ph.D.
Mentor: Stephen Goff, Ph.D.
Columbia University in the City of
New York
New York, NY
$99,000 (2005)
Research Awards
New York HIV research centers
consortium meeting
Sherry Deren, Ph.D.
National Development and Research
Institutions, Inc
New York, NY
$5,000
2008 Rectal Microbicide Satellite
Meeting
Ian McGowan, M.D., Ph.D.
Magee-Womens Research Institute
and Foundation
Pittsburgh, PA
$25,000
T
G L O B A L
INITIATI V E S
he widespread availability of antiretroviral drugs has
transformed HIV/AIDS for many into a manageable condition—at least in the developed world. But in resource-limited regions,
economic constraints, limited healthcare infrastructure, stigma, discrimination, and gender inequality combine to fuel the spread of
the epidemic and prevent people with HIV/AIDS from getting the help they need. More than 90 percent of the 33.2 million people
with HIV/AIDS live in developing countries, and most do not know they are infected. Over the past two decades, amfAR has steadily
expanded its international reach through carefully targeted research, prevention, education, and training initiatives in resourcelimited countries.
The MSM Initiative works in partnership
with activists such as Dr. Steave Nemande
(left), president of AlternativesamfAR Annual Report 2007
16
Cameroun, an organization working on
MSM and HIV/AIDS issues in Douala,
Cameroon, and Dr. Paul Semugoma
(right), a physician in Kampala, Uganda.
Global Initiatives
The MSM Initiative
• To advocate for effective policies and increased funding for
Around the world, men who have sex with men (MSM) suffer
HIV programs for MSM.
that fewer than one in 20 MSM has access to HIV prevention,
The cornerstone of the MSM Initiative is a community
treatment, care, and services. “MSM have been largely ignored
awards program through which amfAR supports the efforts
by both social and public health structures in many countries
of grassroots groups in developing countries to provide HIV
for too long,” stated a recently published study in the journal
prevention, treatment, care, and support services to MSM.
PLoS Medicine. Looking at HIV prevalence rates in 38 low- and
Targeting MSM organizations and networks in Africa, the
middle-income countries, the study found that on average
Caribbean, and Southeast Asia, an initial request for proposals
MSM had a 19.3 times greater chance of being infected than
elicited more than 120 applications—85 from Africa alone—
the general population.
and underscored the enormity of the unmet need. A second
disproportionately high rates of HIV infection. It is estimated
Laws against male-male sex exist in 85 countries around
request for proposals will target groups working in Central and
the world. Even in countries without legal prohibitions against
South America and in Asia and the Pacific, and awards will be
same-sex behavior, pervasive stigma often prevents MSM
announced in 2008.
from accessing HIV/AIDS prevention services or care. Without
appropriate health messages and support, many MSM in these
activities, which aim to increase levels of support from govern-
countries unknowingly engage in behavior that increases
ments and nongovernmental institutions for prevention, treat-
their risk of HIV infection. It is small wonder, then, that HIV
ment, and support services for MSM. They will also advance
prevalence among MSM is as high as 40 percent in Kenya, 27
domestic and international policy efforts to end the stigma,
percent in Ukraine, and 21 percent in Uruguay.
discrimination, and violence that threaten the lives of MSM and
fuel the spread of HIV/AIDS.
It is against this backdrop that amfAR launched the MSM
Initiative in 2007. The Initiative has three primary goals:
The community awards are complemented by advocacy
amfAR’s partners in the MSM Initiative are the United Na-
tions Joint Programme on HIV/AIDS (UNAIDS) and the Global
• To support and empower grassroots MSM organizations;
Forum on MSM and HIV. The Initiative is supported by generous
• To build understanding and awareness of HIV epidemics grants from the Elizabeth Taylor AIDS Foundation, the Elton
among MSM; and
•
TREAT Asia
In the Asia-Pacific region, approximately 4.8
million people are living with HIV and 432,000
became newly infected in 2007. In anticipation
of escalating rates of infection and a potentially
devastating epidemic, in 2001 amfAR launched
Therapeutics Research, Education, and AIDS
Training in Asia—TREAT Asia. This network of
F
Fighting Pediatric AIDS: It Takes a Village
or almost 200,000 children living with HIV/AIDS in Asia, survival
depends on much more than medication. Family and community
support are as important as sophisticated medical care, and
without access to education, nutrition, transportation, and other
necessities, the prognosis for HIV-positive children remains dire.
Dr. Pagakrong Lumbiganon has been treating HIV-positive
children at Thailand’s Srinagarind Hospital, a TREAT Asia site, for
more than a decade and every day she sees the limits of what doctors can achieve.
“As physicians,” she says, “we can only provide maybe 20 percent of what children
hospitals, clinics, and research institutions now
need. With children, HIV infection is not treated just by pills. Children need the care
includes 20 adult and 22 pediatric sites in 14
of family, they have to have friends, they have to go to school. It’s not just medical
countries. TREAT Asia works with civil society to
care.”
ensure the safe and effective delivery of HIV treat-
The importance of a network of care is an article of faith among HIV/AIDS
ment across the Asia-Pacific region, to provide
pediatricians. As TREAT Asia steering committee member Dr. Annette Sohn stated at
treatment and prevention education to healthcare
the network’s September 2007 meeting, “The quality of the collaborative relation-
providers and the HIV/AIDS community, and to
ship between the caretaker and the child will determine the success of treatment.”
conduct clinical research specific to patient
populations in the region.
Across Asia, government funding for HIV/AIDS pediatric treatment rarely covers
support services of any kind. But some TREAT Asia-affiliated pediatric programs
have been able to contrive a variety of innovative strategies to help them offer a
Improving Treatment and Care for Children
Close to 200,000 children are living with HIV/
broader range of services.
Dr. Pagakrong’s pediatric HIV/AIDS team at Srinagarind Hospital has looked out-
AIDS in Asia and it is estimated that only 20
side its own walls for help, gradually establishing relationships with multiple NGOs,
percent of them are receiving the treatment and
each of which supports a different aspect of social and family services.
care they so desperately need. Since most clinical
research has focused on the treatment of adults,
But in spite of her successes, Dr. Pagakrong worries about what will happen to
her young patients as they come into adulthood. Shaking her head firmly, she says,
“We have to do more.”
“The pediatrics
network is unique
in that it is made
up of clinicians who
are on the front
lines of pediatric
HIV treatment and
clinical research
in Asia.”
The pediatric HIV/AIDS team at Srinagarind
Hospital in Thailand has been able to contrive
innovative strategies to help them offer a broader
range of services for HIV-positive children.
Action programme, and the M A C AIDS Fund.
•
17
Global Initiatives
John AIDS Foundation, GlaxoSmithKline’s Positive
little is known about the proper treatment of children with HIV.
generated a range of useful information for researchers and
Pediatricians must grapple with complex questions, such as
physicians across Asia. In 2007 alone, seven reports on treat-
when to initiate treatment, which drugs to use and at which
ment patterns and co-infections were published in prestigious
dosages, and when to switch regimens to avoid side effects
peer-reviewed journals including The Journal of Acquired Immune
or treatment failure. Children face their own psychosocial
Deficiency Syndrome, HIV Medicine, and Clinical Infectious Diseases.
issues, and require care that extends well beyond antiretroviral
An important component of the pediatrics initiative is a
therapy.
pediatric HIV observational database that was established in
To help improve treatment, care, and quality of life for
2007 and is now pooling vital information on the epidemiol-
children living with HIV/AIDS across Asia, a pediatrics initiative
ogy of pediatric HIV in Asia, disease patterns, and treatment
was launched alongside the TREAT Asia network in 2006. The
outcomes. The information gathered and analyzed will help
initiative’s goals are to:
researchers find urgently needed answers to the optimal
treatment of pediatric HIV.
18
• Conduct research that is specific and responsive to the
TREAT Asia also manages the Asia-Pacific section of the
International Epidemiologic Databases to Evaluate AIDS
needs of HIV-positive children in the region;
• Educate and train healthcare professionals in pediatric
(IeDEA), a collaboration established by the U.S. National Insti-
tute of Allergy and Infectious Diseases that began its first year
treatment and care;
• Undertake communications and policy activities that ad-
of operation in 2006. The aim of this ambitious initiative is to
create a global database large enough for detailed study of
dress issues surrounding pediatric treatment and care; and
• Strengthen civil society’s understanding of pediatric HIV/
the spread of HIV infection worldwide and to identify trends in
AIDS and its capacity for the safe and effective treatment of
the use and efficacy of treatments in different regions. TREAT
children with the virus.
Asia is contributing anonymous data to IeDEA from more than
6,000 patients at 44 clinical centers in the Asia-Pacific region,
Global Initiatives
The pediatrics initiative coordinates the efforts and pools
including Australia.
the resources of healthcare professionals and researchers at
Drug resistance represents a significant long-term threat to
22 sites in Australia, Cambodia, China, India, Indonesia, Laos,
the efficacy of antiretroviral therapy. The TREAT Asia Studies
Malaysia, Thailand, and Vietnam. The network represents a
to Evaluate Resistance (TASER) are a collaborative effort by
combined caseload of more than 4,300 children with HIV.
TREAT Asia and the PharmAccess Foundation of the Nether-
lands to monitor the emergence and transmission of HIV drug
“The pediatrics network is unique in that it is made up of
clinicians who are on the front lines of pediatric HIV treat-
resistance in Asia and Africa.
ment and clinical research in Asia,” said Dr. Annette Sohn, a
representative of the pediatrics initiative on the TREAT Asia
Help for MSM
Steering Committee. “Some of us have had years of experi-
TREAT Asia lies at the center of efforts to stem the rising tide
ence with antiretroviral treatment, while others lack access to
of HIV among men who have sex with men in Southeast Asia.
these drugs, but all of us are committed to providing care and
In 2006 it was selected as regional coordination secretariat for
treatment to children with HIV. By coming together, we have
Purple Sky, a network of more than 80 organizations working
an opportunity to develop our regional capacity to conduct
to improve prevention, treatment, and care for MSM in the
multinational research and share clinical expertise.”
Greater Mekong Sub-Region, which encompasses Cambodia, China’s Yunnan and Guangxi provinces, Laos, Myanmar,
Tracking the Epidemic
Thailand, and Vietnam.
Collecting accurate data on patterns of HIV disease, demo-
Purple Sky was organized in 2006, and by the fall of
graphics, modes of transmission, and treatment outcomes is
2007 its advocacy efforts had already made a difference. The
essential to developing and implementing effective treatment
network was instrumental in convincing the governments of
and prevention strategies for the region. The TREAT Asia HIV
Cambodia, China, and Laos to add MSM-specific interventions
Observational Database (TAHOD), the region’s first such
to their national strategic plans on HIV/AIDS.
database for HIV/AIDS, houses anonymous data from more
“This is a huge change,” said Clif Cortez, a member of the
than 3,800 patients at 17 sites. The database has already
Purple Sky Network’s advisory board and USAID’s Bangkok
regional senior advisor. “Prior to the work of the Purple Sky
Inspiring Young Activists
Network, none of the national governments in this region were
The Asian Community for AIDS Treatment and Advocacy
anywhere near being at the table as partners on MSM and
(ACATA) is a TREAT Asia mentoring program initiated in
HIV.”
2005 with support from GlaxoSmithKline’s Positive Action
programme. ACATA has brought young treatment advocates
Education and Training
together from around the region to increase their knowledge
Providing education and training for physicians and other
of HIV/AIDS, build their advocacy skills, share experiences, and
healthcare professionals is essential to improving HIV treat-
connect them to the medical and scientific communities. Most
ment and care. Since its inception, TREAT Asia has sponsored
ACATA members have reached the end of their three-year
and conducted workshops and training sessions in many
training cycle and are considering future projects they may
countries in the region.
undertake together.
In Cambodia, TREAT Asia supports several components of
the National HIV Care Training program. It provides training
Responding to an Epidemic Without Borders
for new opportunistic infection/antiretroviral therapy teams at
As the world grows smaller through increased travel and
district hospitals, support and mentoring visits to new and
migration, preventing the spread of infectious diseases such
existing teams, regional workshops for the teams, and an
as HIV/AIDS becomes ever more urgent. A successful global
annual national symposium on care and treatment.
response to the pandemic must respond to the needs of people
During 2007, TREAT Asia also supported a range of com-
at the local level, strengthen national treatment and preven-
munity education and training programs, notably in Cambodia,
tion efforts, and foster regional cooperation. Such a response
China, Thailand, and Vietnam. In addition to establishing Red
involves listening to many voices, including national govern-
Ribbon Centers through local partnerships in China, which
ments, the medical and scientific communities, grassroots
provide highly effective treatment support and education for
organizations, and individuals in marginalized groups such
people affected by HIV/AIDS, TREAT Asia implemented a treat-
as sex workers, injection drug users, and MSM. Through its
ment literacy training program for women in Cambodia, helped
international initiatives and collaborations, amfAR will continue
create treatment literature with the Thai AIDS Treatment Action
to invest in carefully targeted programs with the greatest
Group, and initiated training for peer treatment educators in
potential for extending and improving lives among the world’s
10 Vietnamese provinces. It also co-facilitated workshops on
most vulnerable populations.
antiretroviral treatment for Cambodian women.
holds an HIV-positive child during a site visit in China.
19
Global Initiatives
Jennifer I-Ching Ho, manager of TREAT Asia’s community programs,
2007 GLOBAL INITIATIVES GRANTS AND AWARDS
All projects listed below were supported by amfAR during the period
October 1, 2006, to September 30, 2007. Grants funded during
fiscal year 2007 but awarded in previous years are shown with the
year of the award in parentheses.
Asia Pacific HIV Observational
Database
20
Matthew G. Law, Ph.D.
National Centre in HIV Epidemiology
and Clinical Research
University of New South Wales
Sydney, Australia
$157,465 (2006–Year 1 Subaward)
$19,904 (2006–Bridge Funding
Grant)
$239,069 (Year 2 Subaward)
TREAT Asia HIV Observational
Database
Global Initiatives
Vonthanak Saphonn, M.D., Ph.D.
National Center for HIV/AIDS,
Dermatology & STDs / Cambodia
National Institute of Public Health
Phnom Penh, Cambodia
Yi-Ming Chen, M.D., Sc.D.
National Yang-Ming University
Taipei, China
Fujie Zhang, M.D.
Beijing Ditan Hospital
Beijing, China
Patrick Li, M.B.B.S.
Queen Elizabeth Hospital
Hong Kong, China
Nagalingeswaran Kumarasamy, M.D.,
M.B.B.S., Ph.D.
YRG Centre for AIDS Research and
Education,VHS
Chennai, India
Sanjay Pujari, M.D.
Institute of Infectious Diseases
Pune, India
Tuti Parwati Merati, M.D.
Udayana University School of
Medicine
Denpasar, Indonesia
Shinichi Oka, M.D.
International Medical Center of Japan
Shinjuku-ku, Japan
Adeeba Kamarulzaman, M.B.B.S.,
F.R.A.C.P.
University of Malaya
Kuala Lumpur, Malaysia
Thira Sirisanthana, M.D.
Chiang Mai University
Chiang Mai, Thailand
Somnuek Sungkanuparph, M.D.
Ramathibodi Hospital
Mahidol University
Bangkok, Thailand
Jun Yong Choi, M.D., Ph.D.
Yonsei University College of Medicine
Seoul, South Korea
TREAT Asia Pediatric HIV
Observational Database
Sydney, Australia
$172,800
Australia HIV Observational
Database
Debra Allen, M.B.Ch.B., Dip Med
Northern Sydney Central Coast Area
Health Services, Holden Street Clinic
Gosford, Australia
Dr. Jonathan Anderson
Carlton Clinic
Carlton, Australia
$7,500 (Year 1 Program Technical
Support Agreement)
Support Agreement)
David Baker, B.H.B.
407 Doctors Pty., Ltd.
Sydney, Australia
Support Agreement)
Support Agreement)
Mark Bloch, M.D.
Holdsworth House Medical Practice
Sydney, Australia
Support Agreement)
Support Agreement)
Christopher Lee, M.B.B.S., M.R.C.P.
Sungai Buloh Hospital
Sungai Buloh, Malaysia
M.B.B.S., Ph.D.
YRG Center for AIDS Research and
Education, VHS
Chennai, India
$15,000
Goa Tau, Master Medicine
Port Moresby General Hospital
Port Moresby, Papua New Guinea
Pagakrong Lumbiganon, M.D.
Khon Kaen University
Khon Kaen, Thailand
$15,000
Dr. Katherine Brown
South East Sydney Illawarra Area
Health Service
Wollongong, Australia
Thanyawee Puthanakit, M.D.
HIV-NAT/Thai Red Cross AIDS Research
Centre
Bangkok, Thailand
$7,500
Andrew Carr, M.D.
St. Vincent’s Hospital Sydney, Ltd.
Darlinghurst, Australia
Virat Sirisanthana, M.D.
Research Institute for Health Sciences
$15,000
John Chuah, M.B.B.S., B.Sc.
Gold Coast Health Service District
Miami, Australia
Kulkanya Chokephaibulkit, M.D.
Siriraj Hospital Mahidol Univeristy
Bangkok, Thailand
$15,000
Basil Donavon, M.B.B.S.
Sydney Sexual Health Centre
Sydney Hospital
Sydney, Australia
Rossana Ditangco, M.D.
Research Institute for Tropical
Medicine
Muntinlupa City, Philippines
Poh-Lian Lim, M.D., M.P.H.
Tan Tock Seng Hospital
Singapore
Praphan Phanupak, M.D., Ph.D.
HIV-NAT/Thai Red Cross Research
Center
Bangkok, Thailand
William Donohue, M.B.B.S.
University of Adelaide
Care and Prevention Program
Adelaide, Australia
Robert Finlayson, M.B.B.S., Dip Ven
Taylor Square Private Clinic
Darlinghurst, Australia
$450 (Year 1 Program Technical
Support Agreement)
Support Agreement)
David Orth, M.B.B.S., Dip Ven
Gladstone Road Medical Centre
Highgate Hill, Australia
Support Agreement)
Support Agreement)
Jennifer Hoy, M.B.B.S.
Victorian HIV Service, Infectious
Diseases Department, Alfred Hospital
Dr. Tim Read
Melbourne Sexual Health Centre
Carlton, Australia
Dr. Eva Jackson
Blue Mountains Sexual Health and
HIV Clinic
Katoomba, Australia
Norman Roth, M.B.B.S., F.A.Ch.S.H.M.
Prahran Market Clinic Pty., Ltd.
South Yarra, Australia
Mark Kelly, M.B.B.S.
The Prince Charles Hospital
AIDS Medical Unit
Brisbane, Australia
Dr. Anuja Kulatunga
Northern Territory Dept of Health &
Community Services, Sexual Health &
Blood Borne Virus Program, Clinic 34
Darwin, Australia
$900 (Year 1 Subaward)
Mun Tong Liang, F.A.Ch.S.H.M.
Nepean Sexual Health Clinic
Sydney, Australia
Simon Mallal, M.D.
Royal Perth Hospital/Department of
Clinical Immunology and
Immunogenetics
Perth, Australia
Anne Mijch, M.B.B.S.
Victorian HIV Service, Infectious
Diseases Department, Alfred Hospital
Darren Russell, Medicine
Cairns Sexual Health Service
Cairns, Australia
Dr. David Smith
Sexual Health and AIDS Services
Lismore, Australia
David Sowden, M.B.B.S.
Nambour General Hospital
Nambour, Australia
Sharon Taylor, C.N.C.
Hunter New England Health, Bligh
Street Clinic, Tamworth Sexual Health
Service
Tamworth, Australia
Ian Woolley, M.B.B.S., F.R.A.C.P.
Monash Medical Centre, Clayton
TREAT Asia Quality Assurance
Scheme
Sydney, Australia
$161,468
$119,623 (2006)
TREAT Asia Studies to Evaluate
Resistance
Sydney, Australia
$165,530
$156,297 (2006)
M.B.B.S., Ph.D.
YRG Centre for AIDS Research and
Education, VHS
Chennai, India
$50,000
Sanjay Pujari, M.D.
Institute of Infectious Diseases
Pune, India
$50,000
F.R.A.C.P.
University of Malaya Clinical
Investigation Center
Kuala Lumpur, Malaysia
$50,000
Christopher Lee, M.B.B.S., M.R.C.P.
Sungai Buloh Hospital
Sungai Buloh, Malaysia
$50,000
Thira Sirisanthana, M.D.
$50,000
Somnuek Sungkanuparph, M.D.
Ramathibodi Hospital
Mahidol University
Bangkok, Thailand
$50,000
Praphan Phanuphak, M.D., Ph.D.
Thai Red Cross Research Center
Bangkok, Thailand
$50,000
TREAT Asia Awards
Treatment literacy project
Pharozin Pheng
Cambodian People Living with HIV/
AIDS Network (CPN+)
Phnom Penh, Cambodia
$10,388
Tenth Bangkok Symposium on HIV
Medicine
Prapahan Phanuphak, M.D., Ph.D.
HIV Netherlands, Australia, Thailand
Research Collaboration (HIV-NAT)
Bangkok, Thailand
$20,000
Support for special analyses of epidemiological and clinical HIV research
Preeyaporn Srasuebkul, M.S.
Sydney, Australia
$48,345
Global Initiatives Awards
Promotion of early CMV retinitis
detection: A definitive teaching tool
David Heiden, M.D.
Pacific Vision Foundation
San Francisco, CA
$8,200
Emergency operating support
Felix Mwanza
Treatment Advocacy and Literacy
Campaign
Lusaka, Zambia
$2,000
Catherine O’Connor, M.B.B.S.,
F.A.Ch.S.H.M.
Livingstone Road Sexual Health
Centre
Marrickville, Australia
21
Global Initiatives
David Ellis, M.B.B.S.
D.A. Ellis Pty, Ltd.
Crofts Harbour, Australia
Support Agreement)
Support Agreement)
E
P U B L I C
P O L I C Y
arly on in the AIDS epidemic,
amfAR established itself as both an effective proponent of comprehensive research,
treatment, and prevention programs and a vigorous opponent of HIV-related stigma
and discrimination. Working with partners in the AIDS community and allies in
Congress, the Foundation was instrumental in securing the passage of key legislation,
including the Hope Act of 1988, the Ryan White CARE Act of 1990, and the Americans with Disabilities Act of 1990. To this day, that legislation forms the bedrock of
the national response to HIV/AIDS.
HIV/AIDS, including 1.2 million Americans, much work remains
to be done to shape domestic and international policies that
adequately address HIV research, treatment, prevention, and
the protection of the rights of people living with HIV/AIDS.
Informed by thorough research and analysis, amfAR is a
highly respected advocate of evidence-based and compassionate HIV/AIDS-related public policy. amfAR’s current advocacy
priorities include:
• Securing necessary increases in funding for AIDS research,
prevention, treatment, and care;
• Advancing a research and policy agenda that addresses the
social, structural, and economic factors that contribute to
the HIV/AIDS epidemic;
“At least a quarter
of people in the U.S.
living with HIV are quite
unaware of their infection.
And people who are
unaware of their infection
are likely to transmit
HIV to others.”
At the briefing, actress Gloria Reuben, who played an HIV-
• Advocating appropriate federal funding for the U.S.
positive physician assistant on the television drama E.R. and is
now an AIDS activist, called for increased awareness and dis-
government’s global HIV/AIDS programs;
• Implementing an evidence-based, national HIV prevention
cussion of HIV. “The thing that disturbs me most is to witness
HIV become pandemic in the black community,” Reuben said.
strategy;
• Repealing the current ban on federal funding for syringe
“AIDS is the number one killer of black women aged 25–34.
How could this be?”
exchange programs;
• Expanding access to treatment and care; and
In February 2007, amfAR co-sponsored a conference in Los
• Safeguarding legal protections for people with HIV/AIDS.
Angeles, It’s All About M.E.E. (Motivation, Education, Empowerment),
which was organized by the Black AIDS Institute to address the
HIV and Vulnerable Populations
spread of HIV among African-American women.
Women make up nearly half of all HIV infections worldwide,
according to the Joint United Nations Programme on HIV/AIDS
Harm Reduction and Prevention
(UNAIDS). In the U.S., the number of new infections among
Numerous scientific studies—including many supported by
women has increased steadily since the mid-1980s. Women
amfAR—have shown conclusively that the distribution of
of color have borne the brunt of this increase, with African-
sterile syringes is effective in preventing the transmission of
American women accounting for two-thirds of new AIDS
HIV and other infections among injection drug users, without
cases among women in 2005. Young women are increasingly
increasing drug use. Despite the evidence, the U.S. persists
vulnerable: by 2005, girls represented 43 percent of teenage
in banning the use of federal funds for syringe exchange and
infections.
other harm reduction measures.
To commemorate World AIDS Day on December 1, 2006,
Although the federal ban remains firmly in place, advocates
amfAR co-sponsored a congressional briefing titled HIV/AIDS in
achieved a major victory in 2007 in Washington, D.C., where
the U.S.: Focusing on the Needs of African-American Women. Panel-
one in 20 residents is living with HIV. In 1998, the federal
ists presented scientific and epidemiological updates and policy
government banned the District of Columbia from using local
recommendations, while testimonials from African-American
taxpayer dollars to fund its own syringe exchange programs.
women and young people illustrated the profound impact that
Since the ban was imposed, amfAR has provided grants to
HIV has on daily life for so many American families. The briefing
support syringe exchange in Washington, D.C., and has been
was co-sponsored by the Sexuality Information and Education
vocal in its opposition to the ban. In 2007, both the House and
Council of the United States (SIECUS) and AIDS Alliance for
Senate finally removed the restrictive legislative language, an
Children, Youth, and Families.
advocacy triumph that was a decade in the making.
With more than 33 million people worldwide living with
23
Public Policy
A
Rethinking the Ground Rules for HIV Testing
“
t least a quarter of people in the U.S. living with
HIV are quite unaware of their infection,” said Dr.
Kenneth Mayer, an HIV specialist who serves on
amfAR’s program board. “And people unaware
of their infection are likely to transmit HIV to
others.”
In the hope of getting more people to be
tested for HIV and thereby reducing rates of transmission, in the fall of 2007
amfAR announced its support for making HIV testing a part of routine healthcare. The move followed a shift by the Centers for Disease Control and Prevention, which abandoned previous guidelines that had called for HIV testing to be
24
performed only in tandem with counseling.
Debates have surrounded HIV testing for many years, remembered Peter
Staley, an amfAR program board member. In the 1990s, “we were still living in a
time of HIV exceptionalism,” he said. “HIV was not treated like other conditions
or other sexually transmitted infections because of the stigma involved and the
shock associated with getting a positive reading from an HIV test.”
“But after the advent of highly active antiretroviral therapy, society came
a long way in its perception of HIV,” Staley explained. “One of the things that
dawned on the medical establishment and activists was that HIV exceptionalism
Public Policy
in itself says stigma. Why shouldn’t this be like a hepatitis test, or cystic fibrosis?
There aren’t all these restrictions on how to diagnose cystic fibrosis, nor should
there be for HIV.”
In his own practice, Dr. Mayer encountered the problems presented by
restrictions on HIV testing. “By creating a special system of having to get explicit
and informed consent and having to mandate specific kinds of counseling and
testing, impediments were being created
for healthcare workers,” he explained.
In recent years, concerns about patient
confidentiality have been assuaged by
broad new federal laws.
After a careful review of the evidence,
amfAR’s Public Policy committee and staff
reached a decision in early 2007. “We
felt that it would lead to broader testing
to uncouple the medical process—the
blood test—from the social process—
counseling,” said Staley. “Ultimately that
would lead to saving more lives.”
This amfAR-supported mobile unit in
New York City provides HIV testing,
syringe exchange, and other harm
reduction resources to those who
most need them.
In November 2006, amfAR sponsored the 6th
Annual Harm Reduction Coalition Conference,
titled Drug User Health: The Politics and the Personal,
in Oakland, California. In February 2007 and
in collaboration with the Community HIV/AIDS
Mobilization Project (CHAMP), amfAR co-sponsored and participated in the planning of an HIV
prevention research advocacy workshop in Los
Angeles to educate community advocates about
the latest research and the need for improved
prevention strategies and technologies.
amfAR also organized a congressional briefing in March 2007 to educate legislators and
their staffs about the calamitous influence of injection drug use on the spread of HIV throughout
Asia and Eastern Europe. Entitled Drug Use Fueling
Epidemics in the East, the briefing featured a panel
of international experts who identified increased
injection drug use and a lack of harm reduction
programs as drivers of the epidemic in those
regions. Duong Truong Thuy of Vietnam, a
member of TREAT Asia’s Asian Community for
AIDS Treatment and Advocacy (see page 19),
submitted a written statement to the briefing. Thuy, who was unable to attend in person
because of U.S. policy restricting visas for people
with HIV, described his experiences as a former
injection drug user and the need for outreach
for drug users in Vietnam. “A lot of people think
‘harm reduction’ sounds criminal,” he wrote.
“But isn’t it more criminal when you know how
to save people’s lives and you don’t do anything
about it?”
amfAR continues to support the only annual
national survey of syringe exchange programs in
the U.S., which is published in the CDC’s
Morbidity and Mortality Weekly Report. And through
a contract with the New York State Department
of Health’s AIDS Institute, the Foundation
administers the distribution of harm reduction
supplies to the state’s 17 authorized syringe
exchange programs. These programs, which also
provide counseling, prevention education, and
medical and addiction treatment referrals, have
served more than 121,000 participants.
Candace Webb, Danielle Warren-Diaz, and actress Gloria Reuben.
Protecting Scientific Integrity
Relief, which has brought treatment to millions in developing
amfAR’s Public Policy program is guided by the need to
countries, has solid bipartisan support. amfAR will continue to
espouse and enact AIDS policies that are firmly rooted in
support these measures and other evidence-based policies that
scientific evidence rather than politics and ideology. The
effectively address the treatment and prevention of HIV in the
Foundation is a founding member of the Caucus for Evidence-
U.S. and around the world.
Based Prevention, a group of more than 60 U.S.-based NGOs
and their international partners dedicated to the promotion of
evidence-based policies for HIV prevention in the United States
and internationally. amfAR is also a member of the Integrity
of Science Working Group, which is spearheaded by the Union
gies Project, and the Coalition to Protect Research, a group
2007 PUBLIC POLICY GRANTS
AND AWARDS
of scientific, medical, and health organizations dedicated to
All projects listed below were supported by amfAR
promoting public health through research, including sexual
during the period October 1, 2006, to September
health research.
30, 2007.
of Concerned Scientists and the Reproductive Health Technolo-
A Shifting Landscape?
There are encouraging signs that the political climate is shifting
in favor of more progressive HIV/AIDS policies. For the first
time in a decade, Washington, D.C., will be able to use its own
funds to support syringe exchange and other harm reduction
programs. Some members of Congress are also pressing for
increases in biomedical research, as well as an end to travel
restrictions that hinder the entry of HIV-positive foreigners into
the U.S. Additionally, the President’s Emergency Plan for AIDS
National Black Women and
HIV/AIDS Conference
Phill Wilson
Black AIDS Institute
Los Angeles, CA
$50,000
Research Advocacy for
HIV Prevention: Skills &
Challenges for Activists
Julie Davids
Community HIV/AIDS
Mobilization Project
(CHAMP)
Providence, RI
$3,000
Syringe Exchange in the US:
State of the Art and State of
Public Support
Don Des Jarlais, Ph.D.
Beth Israel Medical Center
New York, New York
$75,000
HIV’s impact on black women and families. Panelists included (left to right)
25
Public Poliicy
amfAR co-sponsored a World AIDS Day congressional briefing examining
T
E D U C ATION
AN D
INFORMATION
he dissemination of new
knowledge gained from AIDS research is integral to all of amfAR’s programs. But
keeping AIDS in the public consciousness and keeping healthcare professionals
abreast of continually evolving HIV treatment and care strategies requires an
ongoing commitment to education and the distribution of information. Through its
Education and Information program, amfAR provides updates on the latest research
and treatment advances to physicians and other healthcare providers, and helps the
public stay informed through the media, public awareness campaigns, the Internet,
and a range of publications.
“It is important for us
to remember that we’re
whole people, that
we’re not just a virus.”
Continuing Medical Education
Each new development in HIV treatment alters the complex
calculations that physicians must grapple with in their daily
decision making. amfAR is one of only a handful of nonprofit
organizations accredited by the Accreditation Council for
Continuing Medical Education to provide HIV education credits
to physicians. amfAR’s professional education courses benefit
physicians, nurses, nurse practitioners, physician assistants, and
others involved in caring for people with HIV. But the ultimate
benefit resides in improved care for patients who must contend
the power of exercise, of just trying to live your whole life as a
with drug side effects, and lifelong monitoring and adherence
whole human being.”
to treatment.
amfAR co-sponsored the 2nd National Conference on Methamphet-
patients is drug resistance. Over time, a patient’s virus will
amine, HIV, and Hepatitis in Salt Lake City in February 2007. The
inevitably mutate and evade the effects of one or more of
meeting brought together public health officials, physicians,
the drugs in a given regimen. However, new drug classes and
advocates, researchers, and law enforcement personnel to find
evolving treatment strategies offer hope for patients who have
ways to diminish the influence of crystal meth use on HIV and
exhausted other treatment options. From June to September
hepatitis incidence. CME credits were provided to participating
2007, amfAR presented a series of educational programs for
physicians.
physician assistants and nurse practitioners entitled Improving HIV Treatment Outcomes and Care for the Treatment-Experienced
Think Tanks and Symposia
Patient. Attended by more than 550 participants and featuring
The long-term success of HIV prevention and treatment is
case-based interactive presentations integrated with study
inextricably linked with educational programs that meet
data, the CME series was held in Raleigh-Durham, North
current and future needs. To identify and plug education gaps,
Carolina; Albany, New York; San Diego; Los Angeles; Denver;
amfAR organized a series of eight think tanks in 2007 that
Atlanta; Indianapolis; Portland, Oregon; Kansas City, Missouri;
brought together health experts, community members, and care
and Boston.
providers from around the country to share best practices and
develop strategies and goals. Separate sessions for clinicians
amfAR also conducted community forums on drug resis-
tance in 2007—one in Seattle in January and a second in Las
and community members were held in San Francisco, New York,
Vegas in May—titled Understanding Antiretroviral Therapy: Lessons
Chicago, and Miami.
for the Treatment-Experienced Patient. Each forum was attended by
nearly 100 participants, including treatment-experienced
partnered with Columbia University’s Mailman School of Public
individuals, caregivers, social workers, educators, nurses, and
Health to organize a symposium entitled HIV Prevention Among
other healthcare providers. Support for the meetings was
Men Who Have Sex with Men. The symposium, which took place in
provided by Boehringer Ingelheim and Gilead Sciences.
late November, featured an international panel of experts who
discussed the epidemiology of HIV among men who have sex
At the Seattle community forum, panelists discussed new
In commemoration of World AIDS Day 2006, amfAR
treatment strategies, recently approved drugs, and the
with men (MSM), as well as prevention methods, prevention
importance and difficulties of adherence—but they also
challenges among African-American MSM, and healthcare for
emphasized that treatment is only one aspect of living with HIV.
MSM in the developing world.
“It is important for us to remember that we’re whole people,
that we’re not just a virus,” said patient advocate Pat Migliore.
Spreading Knowledge, Raising Awareness
“We have to be really responsible as patients to make sure that
In recent years, efforts to institute abstinence-only sex educa-
we round out the rest of our lives. I’ve heard it again and again
tion in schools across the U.S. have led to a dangerous lack of
in here tonight—the power of prayer, the power of spirituality,
knowledge among many young people about HIV transmission
With drug use continuing to exacerbate HIV infection rates,
27
Education and Information
One of the most serious challenges for longtime HIV
S
Sharing Expertise on Treatment-Experienced Patients
treatment, which have helped to extend the lives
eattle internist Dr. Peter Shalit sees hundreds of patients in his
of people with the virus, have fueled a widening
medical practice, about half of them living with HIV. Over the
belief that HIV/AIDS is no longer a serious illness.
course of his career as an HIV specialist, Dr. Shalit has worked
These developments highlight the ongoing need
to keep his patients healthy, but his choices get much more
for accurate, science-based public information on
complicated when they develop resistance to one or more of
HIV/AIDS.
their drugs.
amfAR’s print and electronic publications,
“It used to be until a couple of years ago that we couldn’t
really do anything for people [with drug resistance] except to
which are distributed in the U.S. and around the
world, help to fill this information gap by providing
say, ‘stay on what you’re on or we’ll give you a cocktail that doesn’t make you sick,
up-to-date news on research developments, HIV/
and hopefully things will kind of stay stable for a while’,” Dr. Shalit said.
AIDS policy, the social and economic impact of
Today, more than 20 anti-HIV drugs are available, but Dr. Shalit and others who
28
and prevention. In addition, recent advances in HIV
the epidemic, and HIV prevention. amfAR News is
care for treatment-experienced patients still confront a daunting challenge. “The
published twice a year and distributed to 70,000
folks who have resistant viruses are not a majority,” he explained, “but treatment
people. A monthly email newsletter reaches more
for them is more sophisticated.”
than 40,000. The TREAT Asia Report, which includes
Along with a small group of HIV experts, Dr. Shalit (son of film critic Gene Shalit)
news on the Asian epidemic and updates on
served on amfAR’s planning committee for the Continuing Medical Education
amfAR’s TREAT Asia program, is a quarterly
(CME) series entitled Improving HIV Treatment Outcomes and Care for the Treatment-
newsletter that reaches an international audience
Experienced Patient (see page 27), and took a leadership role in creating the commu-
of 15,000.
nity education portion of the program. He also assisted with content development
The Foundation’s website, www.amfar.org,
and spoke at the physician and community forums that addressed the topic. “This
receives an average of 55,000 visitors each month.
is an issue a lot of providers are unaware of,” he said. “I try to educate them. It is
Updated daily, the site explains AIDS research and
easy to harm someone by giving them a new regimen and having it fail.
policy developments, and disseminates a wealth of
“This virus is very crafty. It takes advantage of any little opening that a person
information on HIV prevention, testing, epidemiol-
will give it,” Dr. Shalit said. “But my personal feeling is that with proper treatment,
ogy, and amfAR’s programs and activities. amfAR
someone with HIV should have the same life expectancy as someone without HIV.”
also develops and distributes reports, fact sheets,
and issue briefs on a wide range of HIV/AIDS
research and policy issues.
In addition to treating hundreds
of HIV-positive men in his Seattle
practice, Dr. Peter Shalit educates
healthcare professionals on the latest
strategies for treatment-experienced
patients through amfAR’s Continuing
Medical Education programs.
“With proper
treatment, someone
with HIV should
have the same life
expectancy as
someone without
HIV.”
Health Commissioner Dr. Thomas R. Frieden help
launch the NYC Condoms program.
In spring 2007, amfAR sponsored a national survey to
Post, the International Herald Tribune, the San Francisco Chronicle,
assess public perceptions of women living with HIV/AIDS.
The New Yorker, The Advocate, Reuters, the Associated Press,
The results showed pervasive negative views of HIV-positive
CNN.com, LATimes.com and Forbes.com.
women and a high level of discomfort in interacting with
On World AIDS Day 2006, amfAR chairman Kenneth Cole
them. Many of the responses displayed a lack of knowledge
appeared on the Discovery Health television network in public
of how HIV is transmitted and misplaced fear of contracting
service announcements about HIV/AIDS. He also participated
the virus that indicate a pressing need to scale up prevention
in exclusive video and audio interviews on the network’s web-
education efforts. Conducted by Harris Interactive for amfAR,
site and in an iTunes podcast. Also for World AIDS Day, amfAR
the survey questioned nearly 5,000 respondents aged 18–44
CEO Kevin Robert Frost appeared on New York’s WCBS TV
and covered HIV risk and responsibility, the impact of gender-
news to speak about the urgency of addressing the epidemic.
based violence, and women’s access to healthcare and health
amfAR’s ability to make its voice heard internationally is
information, as well as attitudes towards HIV-positive women.
considerably enhanced by the active participation of public
The survey was made possible by grants from Broadway Cares/
figures. Celebrities from the fields of music, film, fashion, and
Equity Fights AIDS and the M•A•C AIDS Fund.
fine arts generously donate their time, talents, and resources
to advance amfAR’s mission and raise funds in support of
Beating the Drum
it. amfAR is especially indebted to Dame Elizabeth Taylor
In an era of short attention spans and furious competition for
and Sharon Stone for their innumerable contributions to the
the media spotlight, keeping AIDS on the public radar screen
Foundation and the cause of AIDS research. Others who gen-
requires continual outreach to the media. As a prominent voice
erously lent their voices and support in 2007 include Woody
on HIV/AIDS for more than 20 years, amfAR is sought after by
Allen and Soon-Yi Previn, Tracy Chapman, Richard Gere, Paris
the media for expert commentary on AIDS research and policy
Hilton, Cheyenne Jackson, Eve Jeffers, Milla Jovovich, Beyoncé
issues. In 2007, amfAR was repeatedly called on to provide
Knowles, Liza Minnelli, Kylie Minogue, Natasha Richardson,
expert commentary on the latest research findings. Outlets that
Julian Schnabel, Liz Smith, Stanley Tucci, Dita Von Teese,
featured amfAR and its researchers included The Washington
Harvey Weinstein, and Michelle Yeoh.
29
amfAR Chairman Kenneth Cole and New York City
G I V IN G
amfAR’s accomplishments in the
fight against AIDS would not be
possible without generous support
from individual and institutional
30
donors. There are many ways you
can join us in our efforts to end
the global AIDS epidemic.
Donate online at www.amfar.org
Write a personal check.
Giving
Make a gift in honor or memory of a loved one.
Include amfAR in your will or other estate plans.
Join the “Friends of amfAR” monthly giving program.
Ask your employer to match your gift.
Designate amfAR in your workplace giving program.
Give a “Partners for the Cure” gift of $1,000 or more.
Consider a gift of stock or other assets.
Attend or sponsor an amfAR benefit event.
Donate goods or services.
For more information,
call us at (212) 806-1600
or e-mail [email protected]
Individual Giving
Generous support from individual donors forms the backbone of amfAR’s efforts to control and eradicate HIV/AIDS. The following
individuals and families contributed or raised $1,000 or more between October 1, 2006, and September 30, 2007. amfAR
acknowledges with gratitude the thousands of other donors whose generous contributions, tribute gifts, and benefit event ticket
Lee and Penny Anderson
Gabriel and Ann BarbierMueller
Angela Barrett
Yannis Bilquez
Jaka Bizilj
David C. Bohnett and Tom
Gregory
Jean R. Boulle
Hermann Bühlbecker
Tim Byrne
Luigi Caiola and Sean
McGill
Donald A. Capoccia
Roberto Cavalli
Fabrizio Cerina
R. Martin Chavez, Ph.D.
Robert and Suzanne Chute
Giuseppe Cipriani
Kenneth and Maria Cole
Ugo Colombo
Kenneth and Patricia Crews
Rex Cumming
Sindika Dokolo
Vladislav Doronin
Umar Dzhabrailov
John and Jennifer Eagle
Amir and Maria Ecker
Walter and Laura Elcock
$10,000–24,999
Frank Aldridge, III and
Brooke Aldridge
Omar Amanat
Louis Andy
Paul Arata and Scott Foster
Nicholas Augustinos and
Curt Kirschner
Steven and Carrie Becker
Christian J. Beherman
Jeff Berg
Christina Bloom
Carla Bruni
Vincent Calcagno
David M. Carrillo and Lisa
Sardegna
Tracy Chapman
Vikram Chatwal and Priya
Sachdev
Steven and Alexandra
Cohen
Dennis and Janette
Mohammed Y. El-Khereiji
Jeff and Regen Fearon
Glenn R. Fuhrman
Gladwin Gill, M.D.
Kenneth Goss and George
Michael
Timothy G. Hanlon
Michael Hirtenstein
Marguerite S. Hoffman
James C. Hormel
Anita M. Jaffe
Bob and Susan Kaminski
Maurice Kanbar
Donna Karan
George and Karen Kollitides
Mathilde Krim, Ph.D.
John and Carol Levy
Michel Litvak
Sheila W. McAdams
Patrick and Suzanne McGee
Michele V. McNeill, Pharm.D.
Alexandra Melnichenko
Jerome and Ann Moss
David J. and Nancy Nasher
Aviv Nevo
Ronald Perelman
John and Amy Phelan
Howard and Cindy
Rachofsky
Michael Rawlings
Geoffrey Raynor
Corrado Riccio
Bruce and Avis Richards
Vincent A. Roberti
Edward Rose, III and
Evelyn P. Rose
Rusty and Deedie Rose
David G. Rosenberg
Nathaniel Rothschild
Daniel and Elizabeth
Routman
Phillip H. Rubin
Lily Safra
Cynthia Sarkis Perros
Alan D. Schwartz
Natalia Selivanova
Gary A. Tigges, M.D.
Donald J. Toumey and
Paul Chen
Edward Walson
Kevin Wendle
Derek and Christen Wilson
Steven Witkoff
Jonas and Nicole Woods
Steve Wozencraft
Michael and Sharon Young
William and Deborah Zabel
Luigi Zunino
Anonymous
Davidson
Bob Dedman, Jr. and
Rachael Dedman
Lord and Lady Luis del
Campo Bacardi
Stuart M. Elsberg
Bess and Ted Enloe
Katherine Flanagan
Judy E. Francis Zankel
Jack P. Freinhar, M.D.
Robert and Ann Fromer
Gordon and Ann Getty
Eliot Glazer
Thomas and Deborah Green
Jon Halpern
Daniella Helayel
Richard and Sally Henriques
Sally Horchow
Howard Katz
Alfiya Kuanysheva
Harry Kubetz and Gary
Burton
Mary Ann and Allen Lassiter
Laurence H. Lebowitz and
Naomi Aberly
John and Eleanor Lemak
Bruce Lipnick
Michael K. Longacre
Bill and Suzanne Marcus
Richard L. Martin
Richard H. Metzner and
Mark Sapitsky
Rodney Miller
Hon. and Mrs. Michael
Misick
Nancy and Clay Mulford
Daniel P. Padnos and
Dexter M. Phillip
Lucilo A. Pena
H. Ross and Sarah Perot
Carol A. Prugh
Nicolas Rachline
William and Catherine Rose
Robert Rosen
John and Lisa Runyon
Carole Bayer Sager and
Robert Daly
Mark Sandelson
Steven R. Shareshian
Samuel and Hannah Shipley
Jim and Jan Showers
Victoria Silvstedt
Barry C. Skovgaard and
Marc O. Wolinsky
Sharon Stone
Harold Stream
Mario Testino and
Stephanie Rutherford
Roderick B. Thomson
Ralph M. Vicinanza
Patrick Wade
Anonymous (4)
$1,000–9,999
Armand Abhari
Celiena Adcock
Warren and Jan Adelson
Gil and Jeannette Adler
Jay L. Althouse and Sally K.
Albrecht
H. John Amiri and Janet
Amiri
Arlen and Michele Andelson
Kurt Anderson
Joseph L. Arena
Elizabeth K. Armstrong
Ralph Arnold, III and John
Hannan
William G. Atmore, M.D.
Raul Avila
Alex Badia
Richard K. Baird, Jr.
Ken and Ginger Baldwin
Ray A. Balestri
Merrill Barlow, IV
David Barnett
Daniel Barney
David Barr and Sam Avrett
Dan Bartley
Ben Barzune
Scott Bass and Dominic F.
Chiarello
Bruce W. Bastian
Alvin H. Baum, Jr.
Leo and Naomi Beck
George W. Beddingfield
Lois Beishir
Pamela and Al Bendich
Hanym Ben-Halim
Jean K. Benjamin
Anthony Bergamo, Esq.
Cary D. Berman and
Roy B. Hamm
Jerome J. Berner
Anthony M. Berson, M.D.
Gerard A. Bertolino
Priscilla Beshears
Lucy and Henry Billingsley
Allen D. Black and Randy
Apgar
Allen L. Blaich
Daniel L. Blakemore
Kurt and Margot Bloch
Daniel and Laura Boeckman
Joseph Boerjes
William and Clare Bohnett
Brian R. Bolke
George and Eleanor Bollag
Paul and Maxine Bradley
Peter Bradley and David R.
Krimm
Scott Brady
Brent Brake
Philip D. Brandt
Stephen Brauer
Zev and Mayling Braun
Arthur L. Brown
Brent Brown
Constance A. Brown
David S. Brown
Gavin Brown
Lloyd R. Brown
Robert Bryan and Julie A.
Jensen
Todd Buchanan
Laurie Burns
James and Debbie Burrows
Judd Burstein
Barbara F. Buzzell
Molly Byrne
Renee Cafiero
Walter M. Cain
Karen Campbell
Jonathan S. Canno
Sherman R. Card
Stephen P. Carlino and
Dennis R. Fee
Frank Carucci
Robert and Dolores
Cathcart
Tracy B. Cather
Satjiv S. Chahil
31
Giving
$25,000+
purchases have helped bring us closer to our goal of a world without AIDS.
32
Giving
Matthew Chang
Martin Samuel Checov
Cameron A. Clarke
Robert W. Clausen, M.D.
Michael P. Clifford and
Robert Levy
Anthony and Catherine
Clifton
Stewart and Kimberley E.
Cohen
Kim Colby
Eric Coleman
Scott Coleman
Michael and Linda Connelly
Patrick and Ginger Connolly
Albert B. Connor
Alfred and Alvina Contarino
Frank P. Conway
Joseph H. Cook
Andrew and Wendy Cookler
Nancy and Bruce Cooper
Richard and Fara Copell
Michael Corman
George B. Cotkin
Tom Crane and Richard
Louie
Christopher Crowley
William L. Cruise
Graham and Kimberly Culp
Mimi F. Cummings
J. Patrick Curry
Timothy and Denise Curry
Michelle Curtis
Allen and Mason Custard
Steven Czekala, D.D.S.
Don and Barbara Daseke
Joan C. Davidow
Sean Davis
Lori and Richard Day
Juliet de Baubigny
Michael and Deborah Dean
Glynn and Sonia Decoteau
Alan S. Dejarnette
Salvatore Delorenzo
David and Sylvia Dennison
Craig Deodede
Victoria A. Derdivanis
Traci Des Jardins
John Desmarteau, M.D. and
Alvin E. Thompson
Henry Detering
William and Heidi Dillon
Michael J. Dion
Salvatore E. Dirschberger
D. Kevin and Lisa Dolan
Paul and Winifred Dooley
Simon D. Doonan
Jason Dorn
Pierre J. Dosogne
Donald G. Dotzauer
Angelique Dove Hatch
Judith A. Dove
Joe Dowling and Siobhan
Cleary
Randall G. Drain
Sheryl A. Dreyer
Michael and Bobbie
Drukman
Ferrell D. Drum
Jeff Dulock
Jay P. Duncanson
Scott H. Dunham and
Barbara Eliades
Thomas M. Dunning
Norman A. Dupont
Charlotte S. Dutka
Stefan and Wendy
Dyckerhoff
Marjorie L. Dyer
James Z. Eakes
Olga Echevarria and
James C. Hudton-Wiley
Dory Eckstein
Israel and Edith Edelstein
Jamshid and Mahshid
Ehsani
Richard and Betsy Eiseman
Leslie El Effendi
John M. Ellenwood
Robert J. Elsen
Thomas and Filomena
Emanuel
Dwight and Claire
Emanuelson
Norman and Susan Ember
Gregg L. Engles
Richard and Tucker
Enthoven
David W. Entsminger
Lucille Z. Epstein
Jeff and Shannon Estes
Richard A. Eustice and
Donric A. Hall
Kenneth J. Evanoski
Caroline L. Everts
William L. Exeter
John and Susan Fabian
Gary T. Farrar
James K. Farrell
Vernon E. Faulconer
Jim Fechtenbaum
Elisha Feder
Dean R. Feldman
Duane Fernandez, Jr.
Mark Fichandler and Paul
Travis
Joseph S. Fichera
Eric K. Fischl
Rebecca and F. Barron
Fletcher
Miriam Fond
Curtis Forsythe
William L. Fortune, Jr. and
Joseph D. Blakley
George Foukas, M.D.
Kevin C. Fox
David Frankel
Bill Freeman
David Fremont-Smith
Phillip French
Tom Freudenheim
Ruthellen Fried, M.D.
Stephen Friedman
Ronald and Carol Friedsam
Robert W. Frierson
Cynthia E. Frost
Charlotte Frye
James W. Gallagher
Jonathan Gans and Abigail
Turin
Melanie J. Garner and
John F. Sienkiewicz
Stanlee Gatti
Earl C. Gauger
David A. Gentry
Kevin D. Gertgen
William and Vanessa Getty
Gary L. Gibson
Raymond and Johnnie
Gillespie
Gregory W. Gingery
Harold H. Ginsburg
William A. Glasgow
Lewis N. Glassman
Richard and Carolyn
Glickstein
Ray H. Goetz
Kay E. Goldberg, Ph.D.,
L.Ac.
Whoopi Goldberg
John and Marcia Goldman
Richard N. Goldman
Andrew D. Goodman and
Myra Rubin
James P. Goodman
Bryan E. Gordon
Harold C. Gordon
Joyce Goss
Randall G. Goss
Judson and Rosalind Gostin
Milton and Barbara Gottlieb
Eliot P. Graham and
John M. Celowanchik
Anthony and Linda Grant
Leslie and Joel Greenberg
Brad Greenspan
Gregory W. Griffith
Thomas J. Gross
Seth Grosshandler and
Kim Wainwright
Michael A. Gulish
Dolph Haas
John and Chara Haas
Alexis B. Hafken
Robert S. Hagge, Jr.
Ricardo Halac
Jeremy and Nancy Halbreich
Kenneth Hale
Howard Hallam
Richard V. Hamilton
Tim and Nancy Hanley
Fredric Hanson
Kevin L. Harder
Holly A. Hardman
Ruth and Rolf Harf
Steven and Nicole Harf
Irwin and Carolyn Harris
Annelise Harstick
Margaret S. Havens
Michael H. Hayes
Brook Hazleton
Dana A. Hearn
Troy P. Heiden
Martin C. Hemsworth
Mark E. Henderson and
Bruce Wolfe
Barry and Lana Hendler
Brett Henne
John W. Hering
Michael Herning
John B. Hickey
Al Hill, III and Elin Hill
Ritchie Q. Ho
Lee and Ann Hobson
Mary J. Holland
Thomas C. Holland
Todd Holland and
Scotch Ellis Loring
Chris and Holly Hollenbeck
Douglas A. Holtquist
Paul and Nadine Hooker
Tony and Kim Horton
Willem Houwink
Jack Z. Hruska
David L. Hughes
Robert G. Hulteng
Arthur F. Humphrey, III
Raye Hurwitz, M.D.
Najah Hussain Al Muntafiq
Julian Iragorri
Joel Isaacs
Mark A. Itkin
Gavin and Martha Ivester
Grace Izmirian
Alyson Jackson
Cheyenne Jackson
Steven N. Jacobson
Henry G. Jarecki
Suzanne Jed
Mrs. Lyndon B. Johnson
Luci B. Johnson
Gregory Jones
Dorothy C. Joseph
Shaji Joseph
Jeffrey Judd and Colleen
Prince
Mark A. Kadzielski
Vinod Kalathiveetil
Al Kamhi
Christopher Kamradt and
Janus Valbak
Donna Kaplan
Joan E. Karan
Mary A. Kautz
Christopher G. Kelly, Jr. and
Etta Lamberti-Kelly
Charles T. Kennedy
J. Christopher Kennedy
Kyle F. Kerr
Bernard Kester
Daniel J. Keyer
Richard M. Kielar and
Christian Zimmerman
Bruce C. Kleiman
David Kleinberg
Michael and Kathleen
Klestoff
Michael and Ruth
Klingensmith
Bryan W. Knicely
Alex J. Kochnuk
William G. Kocol
Kenneth F. Koen
David A. Kourlas
Ronya and George
Kozmetsky
Michael and Shelley Krall
Ella Krasner
Peter and Lisa Kraus
Robert W. Krause, M.D.
Daniele Kucera and
Jeffrey M. Khaner
Mark J. Kulkis
Frances E. Kumashiro
Jeff and Terry Kurz
William Kwan
Chal and Chuok Kwon
Brian and Rachel Ladin
Jonathan Lamensdorf
William and Mary Lamont
Maree B. Larson
Mark H. Laughlin
Frank and Kathleen
Lauinger
Jeff Leatham
Sonia Lee and Alan M.
Grumet
Lois A. Lenahan
Edward C. Lenhart
Carl Levine
Dominique Levy
Jay and Sharon Levy
Scott and Allison Levy
F. Bruce and Diana Lewis
Erica Lieberman
Richard Linebaugh
John S. Lipsey and
John E. Alexander
Steven Lisker
Michael P. Liskowycz
Jeff Little
William E. Little, Jr. and
Helen Little
Ming S. Liu
William and Michelle
Lockhart
Arthur L. Loeb
John Lomibao
George M. Lorenzo
Joseph and Susan Losak
Jesse and Patricia Lovejoy
Mr. and Mrs. Lawrence
Ludgus
Francis A. Luttmer
Ruth Luttmer
2007. More than 20 amfAR supporters took a ten-day trek through the Namib Desert of
Namibia and learned firsthand about the AIDS crisis in sub-Saharan Africa. Trekkers raised
$251,000 for amfAR’s programs, led by Peter McManus of Los Angeles who generated
$40,000.
Helena Buzzeo
Sushama Cisson
Derek Cordier
Rainer Facklam
Julie Gilhart
Patti Gomes
Glenn Isaacson
Rowena Johnston
Natalie Kates
Harry Kubetz
Maura Lee
Peter McManus
Brandon Palacio
Dexter Phillip
Ramneek Rikhy
Sandra Roy
Danielle Schofs
John Tarro
Albert Vaccari
Michael Walsh
Trekkers rest at an abandoned farmstead.
Bobby B. Lyle
Frank and Joan Macero
Thomas S. Magaraci
Todd J. Maldonado
Irving and Harriet Malitson
Eric C. Malley
Carey C. Maloney and
Hermes Mallea
Michael D. Manshel
Claire P. Mansur and
John P. Ryan
Steven Mao
Robert Marc
Norman Marks
Bruce and Gloria
Martindale
Patricia J. Matson
William M. Matthes
Christine Mattsson McHale
and John McHale
David J. Maue and Dave
Gaudette
T. Kirk May, Jr.
Douglas G. Mayberry
Kenneth H. Mayer, M.D.
Mario and Luciana Mazzola
Alexander McAfee
Thomas McArdle
Timothy F. McCabe
Mark N. McConnaughay
William and Patty
McCormack
Andrew McFadden
Cappy and Janie McGarr
James J. McInerney and
Gary R. Fafard
Gordon N. McLeod and
Melanie Grisanti
Casey and Megan
McManemin
Jay McNamara
Suzanne R. McPhee
Rochelle McReynolds
David R. McShane
Victoria L. Meakin
Kathryn D. Meister
Bill Melamed, Jr.
Jeffrey D. Meleski
Ron and Wendy Meltsner
Alvaro R. Menendez
Richard and Ronay
Menschel
Manuel R. Merjil
Julie Mesa
Frank L. Miceli
Janet G. Michaels
Neli P. Mihalkova
Frank and Maryann
Mihalopoulos
amfAR staged its third physical challenge fund-raising event, Trek amfAR in Africa, in May
Morton Milder
Howard J. Miller
Fred and Susan Miller
William and Patrica Miller
Judith R. Minor
Ronald P. Minutella
Presley Mock, M.D. and
Lynn Mock
Ronald and Kerry Moelis
Warren Moen
Cynthia Molstad
Elena J. Mondini
Robert Montagnese
Susan B. Montgomery
Alona Moore
David E. Morales, M.D.
Michael D. Morgan
Bruce and Donna Morse
Jenny S. Morton and Mike
Wilson
John Motondo
Jenny Mullen
Don Mullins
John and Marilyn Murbach
Jerry Nahay
Edward Tyler Nahem
Marty Nealon and Richard
Aellen
Robert O. Newbury
Mark E. Newell and
Jo Ann L. Newell
Adina M. Newman
Paul Newman and
Joanne Woodward
David and Antigoni Newton
Connie Ngai
Mark Niquist
Paula A. North
Rosie O’Donnell
David J. Olesker
Joe Olivo and Jeff Wiggins
Jay W. Oppenheimer
Tom Osborne
Mary A. Ostrom
M. Chris Overby, M.D.
David T. Owsley
Robert K. Ozanne
Jay and Ruthie Pack
Susan L. Page
Sonia G. Palacio
Maxwell G. Paley and
Gregory J. Corrales
Daniel and Amy Palladino
Alvin L. Park
John and Diana Park
Joan Parker
Gary and Pamela Patsley
C. Sprague Paynter
Nivia Pedroza
Thomas E. Pedulla
David N. Pennington
Roberta Perez
Christopher A. Perrault
Robert Perri and John J.
Mini
33
amfAR Donors
Giving
Trek amfAR
34
Giving
Jack M. Perry, Esq.
Richard and Lisa Perry
Marjorie L. Pflaum
Kevin P. Philbin
Eric A. Pike
David N. Pincus
Alden Pinnell
Michael C. Pinson
James C. Pirius
Barry and Penny Platnick
Gloria Polastri
Richard and Karen Pollock
Daniel J. Ponder
Patricia Pope
Adrianna M. Pope Sullivan
Fern Portnoy
Kevin M. Poulos
Joe Powell
Nani B. Powers
Randy M. Presuhn and
Timothy Nguyen
Aleksey Pryadko
Jach Pursel
Kelli and Allen Questrom
Robin O. Quivers
Seth D. Radwell
Jerome and Karen Radwin
William and Marcia Rafkin
John A. Ramelli, III
Jeanne G. Rand
Allison Rao
Karl and Carolyn Rathjen
Jordan H. Rednor
Peter S. Reichertz
Brian Reid and Brett
Brenner
Jose R. Reyes
Anthony J. Richardson
Temple S. Richardson
Walter Rieman in Memory
of Tom Stoddard
Leonard and Peggy Riggs
Timothy A. Robert
Bonnie G. Robins
James E. Rocco
David Rockefeller
Howard Roffman and
Duane Waters
Leila A. Rogalsky
Gregory and Lysa Rohan
George Rosenfield and
Christopher Hoover
Brian Roth
Naomi Rothschild
Sandra A. Roy
Iris R. Rubinfield
Frances E. Ruddell
Peter and Sally Rudoy
Lawrence Ruff
James Saakvitne and
Chi Yuen Chow
Mitchell Salaway
Steven S. Saleh
Dorian P. Sarris
Mitchell and Bonnie
Sassower
Tony M. Scelza
Robert Schaffer
Dennis J. Schank
Leonard J. Schaustal, Jr.
Roger E. Schechter and
Craig P. Ziskin
Steven V. Schmitz
Ronald I. Schnur
Harry Schoening
Danielle Schofs
Katie Schwab
Armond and Cynthia
Schwartz
Carol S. Schwartz
Daniel and Barbara
Schwartz
John Schwartz
Sherwood and Mildred
Schwartz
Steven T. Schwarz and Miles
Kahler
Gerald J. Seibel
James R. Seitz, Jr.
Neil L. Selinger and
Rima Grad
Kristen Sellgren and David
J. Ennis
Dennis Senovich
Leslie Serchuck, M.D.
David M. Serna
Adam Shankman
Lionel Shaw
Jesse B. Shelmire, IV and
Michelle Shelmire
Rodney Sher and Mary
Tobin
William F. Sheridan
Allan P. Sherman
Timothy and Beth Shields
James Shimizu
James C. Shingle
Gresham Jay Shinn, Jr. and
Tim Hurst
Tina Shone
Stephen and Wendy Siegel
Douglas Sills and Todd
Murray
Cameron Silver
Albert and Kimberly Silvera
Mervyn and Deborah
Silverman
Lee Simerman, M.D.
Robert G. Simon and Gilles
DeVoe
John and Betsy Simons
Patricia J. S. Simpson
Rosalyn Sinoway
Catherine H. Skove
Eric and Susan Smidt
Frank C. Smith
Mark D. Smith and John
O’Keefe
Joseph Sokolosky
Nira Soomekh
Murat H. Sor, M.D.
James E. Southworth
Stan Sroka
Christina and Sean St. Clair
Peter Staley and Gary
Schwartz
Kathryn and Timothy
Statton
Sue E. Stedman
Alan and Cathy Steel
Tom and Blake Stephenson
Andrew T. Stewart
Kristin K. Stitz and J. Scott
Coleman
Paul and Gayle Stoffel
Stephen Straty
Steve and Emily Summers
Greg M. Swalwell
Richard F. Swenson
Dale and Denice Swift
Lucille Swindoll
Carol Tacker
Robert F. Tannenhauser
Pamela Tarro
Jason and Leigh Taylor
Jim Taylor and Anthony
Luongo
Julie Taymor
Rick and Sandy Thomas
Paul Thompson
Shirley Thompson
Regine Thorre
Andrew P. Tobias
Gregory A. Tosko
Christopher D. Tower
John Traina
Garry Trudeau and
Jane Pauley
Ivana Trump
Brian C. Trust
Stanley Tucci
Douglas H. Tucker
Richard and Adrienne Tufeld
Matthew D. Tumminello
Sheldon G. Turley, Jr.
Alexander J. Turner
Heather L. Turner
Richard F. Turner
Robert L. Turner
Kathleen E. Tyrrell
Robert D. Uher
Kenneth W. Usher
Mandana Vahabzadeh
James Vergara
Dale E. Verlinger
Tom Vinci
David and Karen Wacker
Gerald and Ellen Wacker
Thomas M. Wade
Stephen Wagner and
Simon Beachley
Barry C. Waldorf
Darren Walker
L. Joseph and Karen Walker
Richard and Jennifer Walsh
William E. Walsh, Jr., M.D.
If you or your organization has been inadvertently omitted from these lists or listed incorrectly, please accept our apologies
and contact amfAR at (212) 806-1732 so that we can adjust our records accordingly.
Neal Ward
Robert L. Warner, M.D. and
Larry Bobel
Marshall Watson and Paul
S. Sparks
Steven G. Wedge
Edward and Betty
Weisberger
Don Weiss
Marco and Joan Weiss
Warren Weitman, Jr.
Doris K. Wells
John Wendell
Mona L. Westhaver
Gary and Nina Wexler
Francis W. White
Hall F. Willkie and Thomas
Craveiro
Richard A. Wilpon
Diane B. Wilsey
Aubin E. Wilson
Brian Wilson
Susan A. Winchell, M.D.
John and Barbara
Winkelman
William T. Winters, Jr. and
Adriana Winters
Andrew Wise
C.R. Wishner
Jack and Lynda Withiam, Jr.
Myron Wojtowycz, M.D.
Derik Woods
Sum Wu
Timothy Wu
Rick Wulff
Gordon Youngman
Ryan Zanin
Larry Zerner and
Graciela Renee Edberg
David Zippel and Mike
Johnson
Anonymous (13)
Institutional Giving
amfAR is grateful to the many institutions large and small that support the fight against AIDS through grants, event sponsorship,
cause-related marketing activities, and in-kind contributions. Major corporate support comes from business sectors ranging from
film, fashion, and fine arts to financial services and pharmaceuticals. Additional generous support is provided by corporate and
Alberta Ferretti SpA
Avanti
Balenciaga
David Bohnett Foundation
Bold Films, Inc.
Broadway Cares/Equity
Fights AIDS, Inc.
Cartier, Inc.
Chi Eta Phi Sorority, Inc.
Chanel, Inc.
Chopard
Christian Dior Couture
Chubb
Concerned Parents for AIDS
Research
The Copley Press, Inc.
de Grisogono USA, Inc.
Denise Rich Music, LLC
Diamond Information
Center
Diesel, SpA
Dubai International Film
Festival
Dutch Ministry of Foreign
Affairs
The Eisner Foundation
Estee Lauder, Inc.
Family Health International
Fashion Accessories Benefit
Ball
Federated Department
Stores Foundation
Bill & Melinda Gates
Foundation
GlaxoSmithKline
Richard and Rhoda
Goldman Fund
The Halcyon Company
Harry Winston, Inc.
Hewlett-Packard Company
JG Events
Elton John AIDS Foundation
Kenneth Cole Productions
Krehbiel Family Foundation
M•A•C AIDS Fund
Merck & Co., Inc.
Moët Hennessy
The Ambrose Monell
Foundation
MTV Networks
Mymetics Corporation
Namakwa Diamonds
Limited
Nassiri Music
Omega Diamonds
Parfums Christian Dior
The Picower Foundation
Plaza Motors of Brooklyn
Ltd.
Quintessentially
Red Pillar Realty LLC
Red Ribbon Foundation
May Ellen & Gerald Ritter
Foundation
Roberto Cavalli SpA
Rock & Republic
Sergio Rossi
Skyy Spirits, LLC
Sotheby’s
Swarovski America Ltd.
The Elizabeth Taylor AIDS
Foundation
Tibotec Therapeutics
Time Inc.
Trade Associates Group Ltd.
Verein AIDS Life
Warner Home Video, Inc.
Wasserman Foundation
The Weinstein Company
Wells Fargo
Yves Saint Laurent
The Ruth/Allen Ziegler
Foundation
Anonymous (4)
$10,000–24,999
The Aliquot Foundation
AMC, Inc.
Bloomberg
Cousins Brett
D & DF Foundation
DaimlerChrysler
Corporation Fund
Dallas Market Center
Disney Worldwide Services,
Inc.
Entendre Limited
Frechette Family Foundation
Gap Inc.
Jean Paul Gaultier
Gilead Sciences, Inc.
The Hagedorn Fund
The Helene Foundation
Initial Entertainment Group
The Karma Foundation
Laurie Kayden Foundation
John & Maria Laffin Trust
Leibowitz and Greenway
Family Charitable
Foundation
Carol Anne Levy Foundation
Liz Claiborne, Inc.
Louis Vuitton
Merchandise Mart
Properties, Inc.
The Non Nobis Solum
Foundation, Inc.
Park Place Motorcars
Adolph and Ruth
Schnurmacher
Foundation, Inc.
Walter H. & Phyllis J.
Shorenstein Foundation
Star Entertainment
Stephen Friedman Fine Art
StepUp Commerce, Inc.
Talcott Communications
Corporation
The Tides Foundation
Title Associates
Torii Pharmaceutical
Company
Waldman Bros.
Theodore & Renee Weiler
Foundation, Inc.
Williams-Sonoma, Inc.
Anonymous
$1,000–9,999
2c design
Abbey Properties, LLC
The Active Network
Adelson Family Foundation
The AEG Family Foundation
American Express
Foundation
Fred & Catalina Aranas
Family Foundation
Astec Power
AT&T California
Avrum Katz Foundation
Azzaro
Bay Area Physicians for
Human Rights
BCM USA, LLC
Bennack-Polan Foundation
Bergman, Walls &
Associates, Ltd.
Bernhardt Showroom
BJ’s Home Accents, Inc.
BlackRock Financial
Management, Inc.
Blue Mountain Arts
Boehringer Ingelheim
Pharmaceuticals
Brian E. Boyle Charitable
Foundation
Bridges/Larson Foundation
Bulgari UK
Bungalow, LLC
Cable Positive, Inc.
Carbon de Luxe
Cars4Charities
Charity Folks
Chelsea Eye Associates
CHIS, Inc.
Christian Dior
Chubb & Son, Inc.
Citibank Private Bank
Cloud 9 of St. Stephen’s
Church
Colorscope
Columbia University
Common Cents New York,
Inc.
Community Foundation of
New Jersey
Craig Nealy Architects LLP
Crawford Communications,
Inc.
CRR Ventures, LLC
David Kleinberg Design
Associates
The Irene Diamond Fund
Diesel U.S.A., Inc.
Discovery Communications
Douglas Foundation
Duro Dyne National
Corporation
Edgell Communications, Inc.
Edward Sulzberger
Foundation, Inc.
Thomas and Jeanne Elmezzi
Foundation
Elmwood Country Club
Nora Ephron and Nicholas
Pileggi Foundation
Equinox Foundation, Inc.
Estilo, Inc.
Extraordinary Investors, Ltd.
Feldman Family 1995
Charitable Lead Trust
Fine Lines Co.
FJC
Flamm Family Foundation
Flaxman Family Charitable
Trust
Fragments Collection, Inc.
Fred B. Bearden, III &
Associates, Inc.
Freeman Decorating
Company
The Abraham Fuchsberg
Family Foundation, Inc.
The Leo & Eva Gans
Foundation, Inc.
Ganz Inc.
Garibaldis on Presidio, Inc.
Gay Men’s Health Crisis,
Inc.
General Maritime
Corporation
George Little Management,
Inc.
GES Exposition Services
35
Giving
$25,000+
family foundations and by a wide range of civic associations, social clubs, cooperatives, schools, and churches.
A Global Cause, A Global Company
M
ajor corporations routinely support charitable causes, but
it takes the dedication of individuals such as HewlettPackard’s Satjiv S. Chahil to champion particular causes,
such as AIDS research. Chahil, senior vice president of
global marketing for HP, has been a driving force behind
HP’s generous support of amfAR at its San Francisco Fall
Gala and Cinema Against AIDS Cannes benefit events.
“It’s a global cause, and HP is a global company,” said
Chahil. But for Chahil, personal experience lies at the root of his commitment. In the 1980s,
when HIV/AIDS was “still a whisper; people weren’t saying it publicly,” a key member of Chahil’s
team at a previous job “withered away because of AIDS.”
36
“We all experienced that firsthand; a whole group of contributors to our industry had been
affected with that one experience,” said Chahil. “When something happens so close to you,
it always has a more profound impact, and unless you are totally unfeeling, you need to do
something about it.”
Satjiv S. Chahil, vice
As a member of an industry that relies on innovative technology, Chahil was quick to see the
president of global market-
value of supporting amfAR’s innovative research. His dedication to raising funds for HIV/AIDS
ing for Hewlett-Packard’s
research was further influenced “by the passion of the people driving the cause,” notably Sharon
Personal Systems Group,
Stone and Dame Elizabeth Taylor. “When the activities are done by people with so much commit-
supports amfAR’s
ment and sense of purpose, it inspires others to be for the cause,” he said.
Giving
innovative research
through corporate giving.
Additionally, Chahil considers it good business to support a cause that is so important to HP’s
key customers, ranging from the entertainment industry to the healthcare and pharmaceutical
industries. At times he has reached into his own pocket in order to bolster a particular charitable
venture.
Chahil believes that if you are passionate about supporting worthwhile causes, the act of
corporate philanthropy becomes much more than just a business transaction. This philosophy
would surely be embraced by founder Dave Packard, who 40 years ago said that simply writing a
check does not end one’s responsibility to a cause.
“If you do something as part of your job, it is nine to five,” said Chahil. “But if you do it as
part of a cause, you never once look at the clock.”
“If you do something as
part of your job, it is nine
to five. But if you do it as
part of a cause, you never
once look at the clock.”
Medco Health
Mediavast
Medical Management
Solutions, LLC
Mellon Bank, N.A.
Merchandise Mart
Properties, Inc.
Mill Management, Inc.
Mission Fish
Missoni USA
Moda Dora Gift and Home
Ltd.
The Morris Foundation, Inc.
The Morse Family
Foundation, Inc.
NARS Cosmetics, Inc.
National Society of
Collegiate Scholars at the
University of Wisconsin–
Madison
NATIXIS
NCH Corporation
New Prospect Foundation
Adina Marta Newman Fund
Newmark & Company
Old South Lighting
OneCoast Network
O’Neil Industries, Inc.
Plasmanet, Inc.
The Playboy Foundation
Premiere Radio Networks
The Louis and Harold Price
Foundation
The Richard and Ann J.
Prouty Foundation
R. Brant Design
Reed Business Information
Reed Family Foundation
Renaissance, Inc.
Richmond American Homes
River Watch Restaurant, Inc.
Roche
Roman, Inc.
The Ronson Family
Philanthropic Fund
Roost
Rosalie and Friends, Inc.
The Rosenberg Group
The Norman & Constance
Sadek Foundation, Inc.
Sales Producers, Inc.
Samsara Foundation
The Sawyer Family Fund
George H. Scanlon
Foundation
Shimoda Design Group
The Susan Stein Shiva
Foundation
Silver Lake Technology
Management, LLC
Sixt GmbH & Co.
Edward C. Smith Charitable
Annuity Trust
The M & H Sommer
Foundation
Sony BMG
Sorenson-Pearson Family
Foundation, Inc.
Sotheby’s International
Realty
Jean L. & Robert A. Stern
Foundation
Studios International
Swartz Family Foundation
Gertrude W. and Edward M.
Swartz Trust
The T. Rowe Price Program
for Charitable Giving
T101 Limited
Tailored Benefits
Taryn Rose International
Toyota Motor Sales, U.S.A.,
Inc.
Universal Studios, Inc.
Urban Studio LLC
The Veneman Group
Vera Bradley Designs, Inc.
Vera Wang Bridal House,
Ltd.
VEST & Associates
Village Capital Inc.
Vincini SpA
Ellen M. Violett and Mary
P.R. Thomas Foundation
Washington Mutual Bank
We All Have AIDS
Western Exhibitors, Inc.
William Morris Agency
Winfield Foundation
The Marilyn and William
Young Charitable
Foundation
Youngblood Ltd.
Zagwear, Inc.
Zarathustra Music, Inc.
Anonymous (2)
Jones Apparel Group USA,
Inc.
Kareli Authors, Inc.
Foundation
Kenneth Ludwig Home
Furnishings, Ltd.
Key Foundation
Kikkerland Design Inc.
Klasse Company, Inc.
Kline Family Foundation
Klub Services, Inc.
KPFF, LLC
Krause Advertising
Land America
Larry L. Luing Family
Foundation
Legend Merchant Group,
Inc.
Lenore Hecht Foundation,
Inc.
Bernard Lewis Charitable
Foundation
L’Oreal USA, Inc.
Lucasfilm Foundation
Lynn Mitchell Group, Inc.
Magna Carta Foundation
The Robert Mapplethorpe
Foundation and Studio
Mark Krueger & Associates,
Inc.
The May Foundation
The Stephanie and Carter
McClelland Foundation
The Eugene McDermott
Foundation
John L. McHugh
Foundation, Inc.
37
Giving
Gess Donor Fund of the
Combined Jewish
Philanthropies
GFI Group
GiftBeat
Gilbert Displays, Inc.
The Gill Foundation
Global Health Strategies
The Joseph Gluck
Foundation
Gochnauer Family
Foundation
Moe Greendale Family
Foundation, Inc.
The Niki and Joe Gregory
Charitable Foundation
Mimi & Peter Haas Fund
Hamlin Capital
Management
Hermes of Paris, Inc.
Samuel and Hannah
Holzman Trust
Home Box Office
Hover Family Trust
The Iacocca Family
Foundation
ICI Worldwide, Inc.
Imtech Graphics Inc.
Iron Mountain Film and
Sound Archives
J.C. Edward Corporation
Margaret G. Jacobs
Charitable Trust
Carl Jacobs Foundation
The Nathan P. Jacobs
Foundation
Jeffers Design Group
Jenny Hammons/Company
IN-KIND CONTRIBUTIONS
In-kind contributions of goods and services—either donated or discounted—are a mainstay of amfAR’s highly successful benefit
events. Ranging from small cocktail parties and store openings to art auctions and international galas, these events play a critical
role in raising vital funds and building AIDS awareness.
amfAR relies on generous contributions by individuals and organizations of in-kind gifts ranging from design and printing of invitations and other materials, catering and beverage services, to auction and gift bag items, floral arrangements, entertainment, and
more. amfAR extends grateful thanks to Kenneth Cole Productions for its many in-kind contributions, including Kenneth Cole
products for meetings and conferences, and to American Airlines for the generous donations of air transportation and related
services that allow the Foundation to keep travel expenses to a minimum.
Since the early days of the epidemic, the art community has supported the fight against AIDS with steadfast generosity. amfAR is
especially grateful to the many artists, galleries, and museums that have contributed to the resounding success of Two by Two for
38
AIDS and Art, an annual dinner and auction of works by renowned contemporary artists that benefits amfAR and the Dallas
Museum of Art. Graciously hosted each year by Howard and Cindy Rachofsky, Two by Two for AIDS and Art has raised a total of
$17 million for amfAR and the Dallas Museum of Art since its inception in 1999.
We thank the following donors for their charitable in-kind donations.
Giving
ART COMMUNITY
IN-KIND
303 Gallery
John Adelman
Ameringer & Yohe
Andrea Rosen Gallery
Angstrom Gallery
Anthony Meier Fine Arts
Anton Kern
Nobuyoshi Araki
Estate of Diane Arbus
Architectural Arts Company
Hope Atherton
Barry Whistler Gallery
Marc Baseman
Michael Bell-Smith
Bellwether
Andrew Bennett
William Betts
bitforms
Bortolami Dayan
Bradly Brown
Jeff Burton
James Lee Byars
Kristin Calabrese
Ingrid Calame
Scott Calhoun
Douglas Leon Cartmel
Justin Carun
Casey Kaplan
John Chamberlain
Charles Cowles Gallery
Cheim and Read
Theresa Chong
Collage 20th Century
Classics
Phil Collins
CRG Gallery
Betty Cunningham
Danese
Christian Dell
Nick Dine
Tomory Dodge
Doner Studio
Michele Oka Doner
Donzella
Dune
Dunn & Brown
Contemporary
David Dupuis
Edward Tyler Nahem Fine
Art
Olafur Eliasson
Elizabeth Dee Gallery
Derek Eller
Tracey Emin
Emily Eveleth
Brian Fahlstrom
Patrick Faulhaber
Mark Ferguson
Thomas Flechtner
Mark Flood
Florence Lynch Gallery
Fort Street Studio, Brad
Davis, and Janis Provisor
Foxy Production
Fraenkel Gallery
Fredericks & Freiser
Stephen Friedman
Tom Friedman
Friedrich Petzel Gallery
Galerie Eigen + Art
Galerie Karsten Greve
Galerie Lelong
Tim Gardner
Anna Gaskell
Gavin Brown’s enterprise
Gerald Peters Gallery
Gladstone Gallery
Goff + Rosenthal
Gorham Manufacturing
Company
April Gornik
Bob Gramsma
Anthony and Linda Grant
Greenberg van Doren
Gallery
Isca Greenfield-Sanders
Theresa Hackett
Trenton Doyle Hancock
Mark Handforth
Haswellediger & Co. Gallery
David Hockney
Nir Hod
Holly Johnson Gallery
Jenny Holzer
Tony Horton
Hosfelt Gallery
Jacqueline Humphries
Pierre Huyghe
Warren Isensee
Jack Shainman Gallery
James Cohan Gallery
Bill Jensen
Jewelers’ Werk Galerie
John Berggruen Gallery
John Connelly Presents
Mado Jolain
Otis Jones
Josee Bienvenu
Oliver Kamm
Seydou Keita
Ted Kincaid
Per Kirkeby
Knoedler & Co.
David Kordansky
Uwe Kowski
Barney Kulok
Sean Landers
Ricardo Lanzarini
D’Nell Larson
Darryl Lauster
Barry Le Va
Jody Lee
Nikki S. Lee
Lehmann Maupin Gallery
Janaki Lennie
José Lerma
Leslie Tonkonow Artworks
+ Projects
Arik Levy
Miranda Lichtenstein
Siobhan Liddell
Justin Lieberman
Luhring Augustine
Eva Lundsager
Magen H Gallery
Marco Maggi
Marc Foxx
Marian Goodman Gallery
Marianne Boesky Gallery
Marty Walker Gallery
Dan McCarthy
Metro Pictures Gallery
Michael Werner Gallery
Jason Middlebrook
moniquemeloche gallery
Sarah Morris
Moss
Ted Muehling
Mulcahy Modern
Nicole Klagsbrun Gallery
Nic Nicosia
David Noonan
Adam Ogilvie
Olafur Eliasson, Werkstatt
& Büro
Jules Olitski
Tom Orr
PaceWildenstein
Carolanne Patterson
Philip Pearlstein
Adam Pendleton
Emilio Perez
Perry Rubenstein Gallery
Danica Phelps
Monica Pierce
John Pomara
R 20th Century
Robert Rauschenberg
Jim Richard
Road Agent
Sergio Rodrigues
Susie Rosmarin
Johnnie Winona Ross
Michal Rovner
Runyon Fine Arts, Inc.
Ed Ruscha
Lisa Sanditz
Sara Meltzer Gallery
Derrick Saunders
Christoph Schmidberger
David Schnell
Björn Schülke
Jeff Scott
Sean Kelly Gallery
Marco Boggio Sella
Richard Serra
Cindy Sherman
Gary Simmons
General In-Kind
A Gourmet’s Pantry
Aaron Barak
Abigail’s
Adios Golf Club
Aiden Gray
Alba Interiors
Alberta Ferretti
Alessandro Dell’Acqua
Joshua Alexander, CMT
American Airlines
Lee and Penny Anderson
Ann Gish
Area San Francisco
Armani Casa
Arte Italica
Arteriors Home
Aspen
Azzaro
Bag, Borrow, or Steal
Bailey Street
Barbara Cosgrove Lamps
Barneys New York
Bass/Chiarello
Bayonne Golf Club
Beatriz Ball
Beauchamp Communications
Bella Rose by Chateau
Bentley Dallas
Berkeley Hotel
Bernardaud
The Biltmore Hotel
Bing Bang
Black Pearl
bliss
Dallas art patrons Cindy and Howard Rachofsky have helped raise
$8.5 million for amfAR through their generous support of the
charity event Two by Two for AIDS and Art, which they have
hosted since 1999.
I
On the Cutting Edge of AIDS and Art
n 1999, amfAR began teaming up with the Dallas Museum of Art for a joint
fundraiser called Two by Two for AIDS and Art, an event designed to rally contemporary art lovers to raise funds for both cutting-edge HIV/AIDS research and
for the museum. When hedge fund investor and art collector Howard Rachofsky
and his wife, Cindy, were asked to host the event at their Richard Meier-designed
home, they were happy to oblige.
Nearly a decade later, the black-tie dinner and art auction has evolved into
one of the city’s premier social events and amfAR’s highest-grossing domestic fundraiser,
generating $8.5 million for amfAR since its inception.
“We were introduced to amfAR when we were asked to host the first event in 1999,”
said Cindy. “We were obviously aware of amfAR’s mission, but over time have really come
to understand its critical role in the fight against AIDS.”
“Maybe we thought it would be a one-time event,” remembered Howard, “but when
they asked if we would be willing to do it again, well, we thought it would be fabulous. The
cause is good, the plan is cogent, and it’s a wonderful opportunity.”
The Rachofskys generously volunteer their efforts in coordinating Two by Two’s local
leadership, assembling a roster of in-kind donors, and, above all, procuring significant
contemporary artwork for auction. Infused with their energy and passion, Two by Two has
evolved from a one-night fundraiser to a week of events, including an exclusive Saturday
night black-tie dinner and auction, after-party, and a Sunday awards brunch where
amfAR presents its Award of Excellence for Artistic Contributions to the Fight Against AIDS.
“It just made sense to support amfAR, and it quickly caught on,” said Cindy. “It
certainly has opened the eyes of many people in our community.”
“Over time we
have really come
to understand
amfAR’s critical
role in the fight
against AIDS.”
39
Giving
Allison V. Smith
John Holt Smith
Ken Solomon
Sonnabend
John Sparagana
Sperone Westwater
Mart Stam
Steuben Glass
Zoe Strauss
Donald Sultan
Sarah Sze
Taka Ishii Gallery
Tanya Bonakdar Gallery
Sam Taylor-Wood
Juergen Teller
Ryan Trecartin and Lizzie Fitch
Richard Tuttle
Lane Twitchell
Lesley Vance
Charline Von Heyl
Michael Wetzel
White Cube
Rachel Whiteread
Christopher Williams
Grant Worth
Yvon Lambert New York
Zach Feuer Gallery
Xiaoze Zie
Andrzej Zielinski
Jeff Zimmerman
Zwirner + Wirth
David Zwirner
40
Giving
BMW
Bold Films
Bonnie Fratis & Associates
Boor Bridges Architecture
Boucheron
Bougainvillea
Boulevard
BR Guest Restaurants
Bradford Renaissance
Portraits
Stephen Brady
Brick Restaurant
Romero Britto
Brooklyn Style Foundation
Brooks & Ian
BRP
Todd Buchanan
Bulgari
Bungalow
Bungalow 8
Burj Al Arab
Calvin Klein
Candle Stick
Carbon De Luxe
Cartier SA
Casa del Bianco
Casa Tua
DJ Cassidy
Chaiken
Chanel
The Chef’s Table
Chelsea Eye & Cosmetic
Surgery Associates
Chez Panisse Restaurant
and Café
Chopard & Cie SA
Chopra Spa
Christian Dior
Giuseppe Cipriani
Clayton Brothers
Coach
The Colbert Report
Mary Colhoun
Collections West
Company C
Compass Home
Completely Bare Spa
The Container Store
Corona Décor
Crabtree & Evelyn
Currey
Cyan Design
Dallas Market Center
Daniel Perry Studios
Daniel Stuart
Danube Restaurant
The Davenport Roadhouse
at The Cash Store
Dean
Decorize
Delfina Restaurant
DEMDACO
Department 56 Sales, Inc.
Diane Von Furstenberg
Diesel
The Dining Room at the
Ritz-Carlton, San Francisco
diPietro Todd Salon
Dolce & Gabbana
Domain Home Fashions
Donna Karan
Jason Dorn
Dubai Duty Free
Duran Duran
Bob Egan
Eileen Fisher
El Raigon Argentine Asado
Elie Saab
Emanuel Ungaro
Emirates Airlines
Molly and Gregg Engles
Enid Alvarez Photography
and Design
Etro and Echo Design
Group
Excalibur
Facestation
Michael and Barbara Faure
Fendi
Feraud
Sarah Ferguson, Duchess
of York
Fine Art Lamps
Fine Lines Co.
Floreal, Inc.
Fosters Point
Four Hands
Four Seasons Hotel,
San Francisco
Fragments
Frédéric Fekkai
Fresh @ Ruby Skye
Frette
Fusion Z
Gallery Designs
Holly Getty
Gianfranco Ferre
Gianni Versace SpA
Givenchy
GoGo Gear
Grey Gardens
Gucci
Hal Boyer
The Halcyon Company
Rich Hamilton
Hammons
Hampton Pet Carriers
Pamela Hanson
Harry Winston
Hayden Harnett
Tim Headington
Hedges
Hen-Feathers
Hermes
Hewlett-Packard Company
Homestead General Store
Hotel (The Mercer)
Hotel Bel-Air
Hotel Villa d’Este
Hugo Boss
The Huntington Hotel and
Nob Hill Spa
IMAX
IMG
Indian Springs Resort
and Spa
The Institute for Culinary
Education
Jardinière
Jean Paul Gaultier
Jeanine Payer
Jeffrey Atlanta New York
Joanne & Company
John Dellaria Salon
John Kane
John Varvatos Enterprises
Jovovich-Hawk
JP Morgan Chase Private
Bank
Judith Leiber
Jumeirah
Jane Kaplowitz
Kauri Cliffs Lodge and
Golf Course, Kerikeri,
New Zealand
Kiehl’s Since 1851
Kiton
Kramer Photography
La Dolce Vita
Ladybug
Lafayette 148 New York
LAFCO New York
LALIQUE
Landor Associates
Laso Group
Alberto and Consuelo
Lataliste
The Late Show with David
Letterman
Lauren Merkin
L’Ermitage
Leslie Street
Ed Libby
Tom Lieber
LightenUp Designs
William E. Little, Jr.
Livia Dumoulin
Lois Lane Travel
Loloi Rugs
Longchamp USA
Louis Vuitton
Luca Luca
M∙A∙C Cosmetics
Magnolia Casual
Mainly Baskets
Manolo Blahnik
Marc Jacobs
Marchesa
Marco Polo Designs
Mariana
David McShane
Mecca
Men’s Youth Skincare
Mexico Boutique Hotels
Michael Kors
MiMa by Eurofly
Liza Minnelli
Kylie Minogue
Missoni
Moët Hennessy
Morgans Hotel Group
Morton’s Steakhouse
MTV Networks
The Myriad Restaurant
Group
Napa Home & Garden
National Golf Links of
America
Nautica
NDI
Neiman Marcus
Lowell Nesbit
New York Knicks
Daniel Nicoletta
Sarah Nix
Nobu Fifty Seven
Nobu Miami Beach
Notre Monde
NY Fitness
Oakley
Old World Designs
Olivia Riegel
Oracle Fountains
Orla Kiely
Orlandi
Padmas Plantation
Palecek
Paper Rad
Paul Smith
Peninsula Humane Society
Perilla
Peter Som
Pierre Olivier Deschamps
Playboy Enterprises
PlumpJack
Postrio
Pout
Prada Handbag
Pratesi
Progress
Project Runway
The Rainbow Room
Ralph Lauren
Random Autograph
Raquels Collection
Brett Ratner
Robert Rauschenberg
Redtoenails
Reinstein/Ross
Hans Reiser, MD
Richard Cohen, Inc.
Riley James
Pat Riley
Rittenhouse
The Ritz-Carlton, San
Francisco
Robert Marc Opticians
Vincent A. Roberti
Roberto Cavalli
Rock & Republic
Rodarte
Rollins Jamaica
Michele Rollins
Sabine Römer
Rob Rosenbluth and
Carolyn Bernstein
Rug Market
Safari
San Francisco Symphony
Sand Castle Winery
Sapa
Saro Trading Company
Savim USA/Fornasetti
Julian Schnabel
Seasonal Living
Sebonic Golf Club
Monica Seles
Serendipity 3
Sergio Rossi
Shear Bliss
Sheila Kelley’s S Factor
Hannah and Samuel Shipley
Kimora Lee Simmons
Smart Workout
Smorgas Chef Restaurants
Sony/BMG Music
Entertainment
South of France
John Eric Sparacio
Stella McCartney
Mr. and Mrs. Spook Stream
Style Paris
stylicon
Sunset Tower Hotel
Superdeluxe
TAG
Mario Testino
Michael Tilson Thomas
Tinicum Civic Association
Tivol Studios
Todd Event Design
Duane Tollison
Tommy Toy’s Cuisine
Chinoise
Toss Designs
Travel Planners
Tres Agaves Mexican
Kitchen & Tequila Lounge
Trump International Golf
Club
TUMI
Turner Sports Broadcasting
Tzell Travel
Until There’s A Cure
Uttermost
Valentino
Vice Versa
Victoria’s Secret
Corporation
Vietri
Vikram Chatwal Hotels
Village Divers
Vintage Verandah
Visual Comfort
Walnut Street Theatre
Gemma Ward
Waterford
William Wegman
Janet Weiner
The Weinstein Company
Well Box
Williams-Sonoma Home
Steven Witkoff
Frank Yamrus, Gregory Lind
Gallery
Yves Saint Laurent
Zac Posen
Durwood Zedd
Zodax
Zuni Café
T
A Landmark Bequest
hose who knew philanthropist Ric Weiland well
may not have been surprised to learn that his will
included generous provisions for his favorite charitable causes. But few could have anticipated that,
upon his tragic death in 2006, Weiland would
leave $8 million to amfAR.
The bequest will be paid out through install-
ments over the course of the next eight years, providing a stable funding
stream that allows amfAR to respond to emerging challenges in the HIV/
AIDS epidemic with speed and flexibility.
company’s first five employees. He worked as a project leader, lead programmer, and developer for Microsoft’s BASIC and COBOL personal computing
interfaces.
He left Microsoft in 1988 and began to devote his energies to charitable
work. Rather than start his own foundation, he chose instead to give tens
of millions of dollars to various organizations. Weiland carefully reviewed
the programs and finances of the charities he chose to support and resisted
public acknowledgment of his generous giving.
“For many years Ric Weiland was one of amfAR’s most generous and
knowledgeable individual donors,” said amfAR’s CEO, Kevin Robert Frost.
“His dedication and commitment to our work in ending the global AIDS
epidemic was an inspiration to us all.”
Weiland died in June 2006 at the age of 53, after a long battle with
depression. The bulk of his estate went to establish the Weiland Designated
Philanthropist Ric Weiland—one of
Microsoft’s first five employees—
bequeathed $65 million to national gay
rights and HIV/AIDS organizations,
including $8 million to amfAR.
Fund, to be managed by the Seattle-based Pride Foundation, with $65 million allocated to a group of national gay rights and HIV/AIDS organizations.
“Ric wanted to be sure that his contributions would be used
effectively and efficiently to help improve and extend lives—in amfAR’s
case, the lives of people living with HIV/AIDS,” said Frost. “As a donor to
amfAR, Ric gave both with his head and with his heart.”
“Ric wanted to be sure that his contributions
would be used effectively and efficiently to
help improve and extend lives—in amfAR’s
case, the lives of people living with HIV/AIDS.”
41
Giving
1975—the year they founded Microsoft—and became one of the software
Weiland joined his high school classmates Bill Gates and Paul Allen in
PLANNED GIVING
Planned, or deferred, giving is a farsighted investment in the future. Generous bequests and other planned gifts help ensure that
amfAR can sustain its support of innovative HIV/AIDS research programs over the long term. Between October 2006 and September
2007, the Foundation was the grateful beneficiary of the planned gifts listed below, including particularly generous legacies from
Gertrude Horowitz, Marie Eliopoulos, Martin F. and Irene R. Murphy, and Lorraine E. Cantor.
amfAR received gifts from the estates of
42
Maureen E. Bacchi
Michael F. Bennett
Mary G. Brakefield
Mildred Burg
Lorraine E. Cantor
Herbert Chiltern
Gladys Chinn
Marilyn Joyce Colbert
Frances M. Corrao
Susan Ethel Cox
Aileen Cramer
John Perryman Davidson, III
Wilfred W. and Ruth J. Davies
Claire E. Dick
Jean Eastman
Marie Eliopoulos
Lillian and Frank Fields
Jill & Jayne D. Franklin
Edith Hollander Goldberg
Frank L. Gulizia
Gertrude Horowitz
Bertha M. Jacobson
Steven D. Kaeser
Gertrude Kartzmer
Andrew Kott
Olive M. Laubenthal
Michael Le Clair
Robert C. Lees
Jerome H. Lever
Ralph A. Ludlow
David Edward MacArthur
Galeb H. Maher
Francisco Martin
Donna M. Mellem
Dorothy Merdian
Michael Metzger
Alice Ruth Meyer
Margaret W. Midgett
Joan Mills Miller
May M. Moore
Marice Murphy
Martin F. & Irene R. Murphy
Jannette Powell
James Michael Rampe
Peter P. Rossi
Roberta Schecter
Winifred E. Shaheen
Joseph L. K. Snyder
Freda Sobel
Robert C. Tesch
James Gordon Umberger
Richard W. Weiland
Thelma and Clyde West
Roy Glenn Wood
VOLUNTEER SUPPORT
Giving
amfAR’s Board of Trustees, Program Board, and Scientific Advisory Committee are composed entirely of individuals who generously
volunteer their time, professional expertise, and financial resources to the Foundation’s benefit. These core volunteers span a range
of backgrounds and areas of expertise and include scientists, physicians, academics, and business leaders. In some locales, notably
Dallas, Philadelphia/Bucks County, and San Francisco, committed individuals have established volunteer steering committees and
have organized benefit events that help attract new supporters and build awareness of amfAR’s work.
In addition, amfAR is fortunate to enjoy the support of many celebrities from the fields of art, fashion, film, music, haute cuisine,
publishing, and television who generously donate their time and talents to the Foundation’s benefit events. amfAR is especially
grateful for the dedicated support of its founding international chairman, Dame Elizabeth Taylor, and Sharon Stone, global
fundraising chairman, who remain highly visible and effective spokeswomen for the Foundation.
For many years, amfAR has benefited enormously from the steadfast support of three unique volunteer organizations:
Concerned Parents for AIDS Research (CPFA) was created in 1989 by a group of parents who, spurred by Alison Gertz’s public
revelation that she had AIDS, realized that young people everywhere were at risk. CPFA seeks to secure an AIDS-free future by
funding basic biomedical and clinical research to develop a preventive vaccine and a cure for HIV/AIDS, and by working to raise
AIDS awareness and encouraging parents to become actively involved in finding a solution to this public health crisis. Since its
inception, CPFA has raised $4 million for AIDS research.
Gift for Life (GFL) is a nationwide group of volunteers from the gift, stationery, tabletop, and decorative accessories industries
who raise funds for AIDS research and build awareness among friends and colleagues. Founded in 1992, GFL has generated more
than $4 million in support of amfAR’s programs.
The Bucks County Committee is part of the Greater Philadelphia community, which was among the first to respond to the AIDS
crisis in this country. To date, these donors have contributed more than $4.5 million to amfAR, which the Foundation has used to
GFL Board of Directors
Arun Agarwaal
John Amiri
Tabitha Bowling
Sheila Charton
Mary Liz Curtin
Cole Daugherty
Sharon Davis
Mike Dean
Debra Gold
Lisa Goodman
Jenny Hammons
Su Hilty
Kathy Krassner
Terence Morris
David Moses
Michael Ruddell
Jill Sands
John Saxtan
Peter Schauben
Gerry Seibel
Warren Shoulberg
Cathy Steel
Paul Thompson
Laura Van Zeyl
Joyce Washnik
Nancy Wolkow
Bucks County Committee
Randy Apgar
Scott Bass
Allen Black
Bob Egan
Sally and Richard Henriques
Greg Kammerer
David Lewis
Jim McClelland
David McShane
Lynn Miller
Doug and Betsy Rendall
Renny Reynolds
Kenneth G. Schaefer
Sam and Happy Shipley
Jack Staub
David Topel
Fred White
Celebrity Volunteers
Casey Affleck
Ted Allen
Woody Allen and Soon-Yi Previn
Kevin Bacon
Ellen Barkin
Mischa Barton
Naomi Campbell
Tracy Chapman
Don Cheadle
George Clooney
Sofia Coppola
Matt Damon
Rosario Dawson
Harold Dieterle
Thom Filicia
Andy Garcia
Richard Gere
Whoopi Goldberg
Elliott Gould
Greg Grunberg
Tim Gunn
Jerry Hall
Marcia Gay Harden
Goldie Hawn
Paris Hilton
Dennis and Victoria Duffy Hopper
Elizabeth Hurley
Cheyenne Jackson
Sir Elton John and David Furnish
Eve Jeffers
Milla Jovovich
Nicole Kidman
Beyoncé Knowles
Julian Lennon
Carey Lowell
Diego Luna
Elle Macpherson
Sophie Marceau
Jesse L. Martin
Jack McBrayer
Rose McGowan
Eva Mendes
Liza Minnelli
Kylie Minogue
Liam Neeson
Petra Nemcova
Cynthia Nixon
Rosie O’Donnell
Orfeh
Aishwarya Rai
Anthony Rapp
Brett Ratner
Natasha Richardson
Robert Rodriguez
Kurt Russell
Claudia Schiffer
Julian Schnabel
Kyra Sedgwick
Chloë Sevigny
Garry Shandling
Liz Smith
Kevin Spacey
Barbra Streisand
Sharon Stone
Dame Elizabeth Taylor
Tracie Thoms
Stanley Tucci
Dita Von Teese
Gemma Ward
Kerry Washington
Sigourney Weaver
Harvey Weinstein
Robin Williams
Michelle Yeoh
WORKPLACE GIVING
Workplace giving programs allow donors to direct a percentage of each paycheck or a fixed dollar amount to amfAR. Among the
many generous individuals who contribute in this way are federal employees and U.S. military personnel who make donations
through the Combined Federal Campaign (CFC). amfAR is listed with the CFC as AIDS Research Foundation (amfAR), and our CFC
designation number is 11996. amfAR is represented in the CFC by Community Health Charities, a federation of national health
agencies. Other donors make their contributions through state and municipal employee campaigns, United Way “write-in” designations, and independent corporate workplace giving programs. amfAR is deeply
grateful to the companies and agencies that allow it to participate in their
campaigns and to the many individuals who direct their workplace contributions to the fight against AIDS.
43
Giving
CPFA Executive
Board of Directors
Andrea Acker
Roberta Bogen
Ivy Duneier
Marjorie Emden
Carol Gertz
Annie Gilbert
Rosalind Glaser
Dr. Andrew Lipschitz
Eileen Mitzman
Lois Nipon
Tina Simner
Rory Teitelbaum
Wendy Wetchler
provide grants and fellowships to 80 Philadelphia-area researchers.
FINAN C IA L
S U MMAR Y
FROM THE TREASURER AND THE CHAIR OF THE
FINANCE AND BUDGET COMMITTEE
The fiscal year ending September 30, 2007, was a period of solid growth and financial stability for amfAR, The Foundation
for AIDS Research, and we are pleased to present a summary of the audited financial statements from this period.
The Foundation was able to exceed its ambitious fundraising goal, generating a total of $23.8 million in public support
and revenue—a 30 percent increase over the previous year. A low supporting services ratio—the ratio of fundraising and
management expenses to total support and revenue—of 18.5 percent demonstrated a high degree of operating efficiency.
Another key fiscal indicator, the program spending ratio, came in at a robust 76.9 percent—meaning that 76.9 cents out
of every dollar spent was invested directly in vital program activities.
The Foundation ended the year with an operating surplus of $4.8 million. This was largely the result of a resoundingly
successful benefit events season, which generated an unanticipated 47 percent increase in revenues over the previous year.
That funding surplus allowed amfAR the flexibility to move quickly in establishing two important new initiatives. The
Mathilde Krim Fellowships in Basic Biomedical Research provide a much-needed funding stream for bright young scientists
seeking innovative solutions to HIV/AIDS. And the MSM Initiative seeks to address and reverse the alarmingly high rates of
HIV infection among men who have sex with men (MSM) in resource-limited countries. Moving from concept to funding in
less than a year, amfAR was able to scale up these programs on short notice, and announced initial grants for both just a
few months after the close of the fiscal year.
44
In 2007, amfAR again met the stringent requirements of governance and financial accountability demanded by the Better
Business Bureau’s Wise Giving Alliance and the federal government’s workplace fundraising program, the Combined Federal
Campaign, as well as many state employee workplace giving campaigns.
Financial Summary
A copy of the complete audited financial statements, prepared in accordance with generally accepted accounting principles
for not-for-profit organizations as established by the American Institute of Certified Public Accountants, is available upon
request from amfAR at 120 Wall Street, 13th Floor, New York, NY 10005, and can be accessed online at www.amfar.org.
Wallace Sheft, C.P.A.
Michael J. Klingensmith
Treasurer
Chair, Finance and Budget Committee
Public Support and Revenue
Investment income
and other revenue:
Expenses
Management
and general: 8.9%
3.5%
Government
funding: 17.3%
Fundraising: 14.2%
Contributions
79.2%
Program Services
76.9%
45
Financial Summary
Total expenses
$18,998,904
Change in net assets
4,797,520
Net assets, beginning of year
15,168,021
Net assets, end of year
$19,965,541
STATEMENT OF FINANCIAL POSITION
Assets
Cash and investments
$21,631,048
Pledges and receivables, net
1,624,941
Prepaid expenses and other assets
453,871
Merchandise inventory and donated assets
513,869
Furniture, equipment, and leasehold improvements, net
840,517
Total assets
$25,064,246
Liabilities
Accounts payable and accrued expenses
$1,267,408
Grants and fellowships payable, net
1,835,159
Deferred support and refundable advances
1,429,967
Other long-term liabilities
566,171
Total liabilities
$5,098,705
Net assets
Unrestricted
$14,848,535
Temporarily restricted
4,815,046
Permanently restricted
301,960
Total net assets
$19,965,541
Total liabilities and net assets
$25,064,246
STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS
For the year ended September 30, 2007
Public Support and Revenue
Public support
$7,155,947
Special events
9,741,974
Planned giving
1,947,199
Government funding
4,105,703
Investment income and other revenue
845,601
Total public support and revenue
$23,796,424
Expenses
Research $7,577,791
Global initiatives
2,585,001
Public policy
1,081,867
Education and information
3,366,625
Total program services
$14,611,284
Fundraising
$2,691,494
Management and general
1,696,126
Total supporting services
$4,387,620
For complete audited financial
statements, visit www.amfar.org
L e a d e r s h i p
Board of Trustees
2007
Chairman of the Board
Kenneth Cole
Chairman and Chief Executive Officer
New York, NY
46
Vice Chairman
Patricia J. Matson
Senior Vice President,
Communications (emerita)
ABC, Inc.
New York, NY
Vice Chairman
John C. Simons
Managing Partner
Corporate Fuel Partners, LLC
New York, NY
Leadership and Advisory Committees
Treasurer
Wallace Sheft, C.P.A.
Partner
Sheft & Co.
Westbury, NY
Secretary
William D. Zabel, Esq.
Senior Partner
Schulte Roth & Zabel, LLP
New York, NY
Founding International
Chairman
Dame Elizabeth Taylor, D.B.E.
Actress
Bel Air, CA
Founding Chairman
Adjunct Professor
Mailman School of Public Health
Columbia University
New York, NY
a n d
Adv i s o r y
TRUSTEES
Arlen H. Andelson
Andelson Properties
Los Angeles, CA
Harry Belafonte
President
Belafonte Enterprises, Inc.
New York, NY
David Bohnett
Chairman
David Bohnett Foundation
Beverly Hills, CA
Zev Braun
President and Chief Executive Officer
Braun Entertainment Group, Inc.
Beverly Hills, CA
Jonathan S. Canno
New York, NY
Donald A. Capoccia
Managing Principal and Founder
BFC Partners
New York, NY
Jane Breckenridge Eisner
President
The Eisner Foundation
Bel Air, CA
Arnold W. Klein, M.D.
Professor of Medicine/Dermatology
University of California, Los Angeles
Beverly Hills, CA
c o m m i t t e e s
Edward L. Milstein
Co-Chairman
Milstein Brothers Capital Partners
New York, NY
Natasha Richardson
Actress
New York, NY
Mario Stevenson, Ph.D.
Director, Center for AIDS Research
Professor, Program in Molecular
Medicine
University of Massachusetts Medical
School
Worcester, MA
Vincent A. Roberti
Chairman and Chief Executive Officer
Palisades Media Corporation
New York, NY
HONORARY TRUSTEES
Allan Rosenfield, M.D.
Dean and DeLamar Professor
of Public Health
Columbia University
New York, NY
John F. Breglio, Esq.
Paul, Weiss, Rifkind, Wharton &
Garrison
New York, NY
Alan D. Schwartz
President
The Bear, Stearns Companies, Inc.
New York, NY
Mouna E. Ayoub
Paris, France
Robert L. Burkett
The Carmen Group
Washington, D.C.
Michael Fuchs
New York, NY
Diana L. Taylor
Managing Director
Wolfensohn & Co.
New York, NY
Sandra Hernández, M.D.
The San Francisco Foundation
San Francisco, CA
Kevin Wendle
Entrepreneur
New York, NY; Paris, France
Sherry Lansing
Chief Executive Officer/Founder
The Sherry Lansing Foundation
Los Angeles, CA
ADJUNCT TRUSTEES
Jane F. Nathanson
Psychologist
Chair, Jane and Marc Nathanson
Community Foundation
Los Angeles, CA
Executive Vice President
Time Inc.
New York, NY
David E. Bloom, Ph.D.
Chair, Department of Population and
International Health
Harvard School of Public Health
Boston, MA
Michele V. McNeill, Pharm.D.
Chairman
McNeill Family Foundation
Long Boat Key, FL
Partner
Goldman, Sachs & Co.
New York, NY
Richard H. Metzner
Principal
Metzner-Schneider Associates
Dallas, TX
Mervyn F. Silverman, M.D., M.P.H.
President
Mervyn F. Silverman Associates, Inc.
Crockett, CA
The Rev. Dr. Randolph Nugent
General Secretary (ret.)
General Board of Global Ministries
United Methodist Church
New York, NY
Pauline Phillips
Nationally Syndicated Columnist (ret.)
Los Angeles, CA
Joel D. Weisman, D.O.
Physician
Rancho Mirage, CA
Chair, Public Policy Committee
David E. Bloom, Ph.D.
Chair, Dept. of Population and
International Health
Harvard School of Public Health
Boston, MA
IN MEMORIAM
Sheldon W. Andelson, Esq.
Mrs. Albert D. Lasker
Jonathan M. Mann, M.D., M.P.H.
Maxine Mesinger
Peter Scott, Esq.
Tom Stoddard
Global Fundraising
Chairman
Sharon Stone
amfAR AMBASSADORS
Milla Jovovich
Liza Minnelli
Michelle Yeoh
Program Board
Chair
Dean and DeLamar Professor
of Public Health
Columbia University
New York, NY
Chair, Global Initiatives
Committee
Mervyn F. Silverman, M.D., M.P.H.
President
Mervyn F. Silverman Associates, Inc.
Crockett, CA
Vice Chair, Public Policy
Committee
Margaret (Peggy) Hamburg, M.D.
Vice President for Biological Programs
Nuclear Threat Initiative
Washington, D.C.
Chair, Research Committee
Mario Stevenson, Ph.D.
Director, Center for AIDS Research
Professor, Program in Molecular
Medicine
University of Massachusetts Medical
School
Worcester, MA
Vice Chair, Research
Committee
Sherry Deren, Ph.D.
Director
Institute for AIDS Research
Center for Drug Use and HIV
Research
National Development and Research
Institutes, Inc.
New York, NY
Mathilde Krim, Ph.D., ex officio
Adjunct Professor
Columbia University
New York, NY
members
Dawn Averitt Bridge
Founder
The Well Project
Nellysford, VA
Tim Brown, Ph.D.
Senior Fellow, Population and Health
Studies
East-West Center
Honolulu, HI
Alex Carballo-Diéguez, Ph.D.
Associate Professor and Research
Scientist
HIV Center for Clinical & Behavioral
Studies
New York State Psychiatric Institute
New York, NY
Willard (Ward) Cates, Jr., M.D.,
M.P.H.
President, Research
Family Health International
Durham, NC
R. Alta Charo, J.D.
Warren P. Knowles Professor of Law
& Bioethics
University of Wisconsin Law School
Madison, WI
Grant N. Colfax, M.D.
Director of HIV Prevention and
Research
San Francisco Department of
Public Health
San Francisco, CA
Hoosen (Jerry) Coovadia, M.D.
Victor Daitz Professor of HIV/AIDS
Research
Doris Duke Medical Research Institute
Nelson Mandela School of Medicine
University of KwaZulu Natal
Congella
South Africa
Carl W. Dieffenbach, Ph.D.
Director, Basic Sciences Program
Division of AIDS, NIAID
Bethesda, MD
Wafaa El-Sadr, M.D., M.P.H.
Chief, Division of Infectious Diseases
Harlem Hospital Center
Professor of Clinical Medicine and
Epidemiology
Columbia University
New York, NY
Sherry Glied, Ph.D.
Professor and Chair
Department of Health Policy and
Management
Columbia University
New York, NY
Jennifer Kates, M.A., M.P.A.
Vice President and Director, HIV
Policy
Kaiser Family Foundation
Washington, D.C.
Patrick Chung-ki Li, M.B.B.S.
Chief of Service
Department of Medicine
Queen Elizabeth Hospital
Hong Kong SAR, China
Kenneth H. Mayer, M.D.
Professor of Medicine and Community Health
Brown University/The Miriam
Hospital
Providence, RI
William E. Paul, M.D.
Chief, Laboratory of Immunology
National Institute of Allergy and
Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Bethesda, MD
Peter R. Staley
Founder & Editor
AIDSmeds.com
Brooklyn, NY
David Vlahov, Ph.D.
Director
Center for Urban Epidemiological
Studies
New York Academy of Medicine
New York, NY
Michael D. Shriver
Co-Director, AIDS Policy Research
Center
AIDS Research Institute
San Francisco, CA
Vice Chair, Global Initiatives
Committee
F.R.A.C.P.
Professor
Head of Infectious Diseases Unit
Department of Medicine
University of Malaya
Kuala Lumpur
Malaysia
47
Leonard Rabinowitz
President
Studio CL
Los Angeles, CA
BOARD COMMITTEES
Executive Committee
Kenneth Cole, Chair
Donald A. Capoccia
Patricia J. Matson
Wallace Sheft, CPA
John C. Simons
Audit Committee
Wallace Sheft, CPA, Chair
John C. Simons
48
Board Development
Committee
William D. Zabel, Esq., Chair
Zev Braun
Jane B. Eisner
Arnold W. Klein, M.D.
Patricia J. Matson
Alan Schwartz
Compensation &
Organizational
Development Committee
John C. Simons, Chair
Richard H. Metzner
Finance & Budget Committee
Michael J. Klingensmith, Chair
Vincent A. Roberti
John C. Simons
Fund Development Committee
Donald A. Capoccia, Chair
Jonathan S. Canno
Edward L. Milstein
Vincent A. Roberti
Scientific advisory
committee
Mario Stevenson, Ph.D., Chair
Sherry Deren, Ph.D., Vice Chair
Rafi Ahmed, Ph.D.
Angela Aidala, Ph.D.
Jonathan S. Allan, D.V.M.
Katheryn Anastos, M.D.
Deborah Anderson, Ph.D.
Warren A. Andiman, M.D.
Peter S. Arno, Ph.D.
Julia Arnsten, M.D., M.P.H.
Larry O. Arthur, Ph.D.
Marcel A. Baluda, Ph.D.
Robert B. Belshe, M.D.
Samuel A. Bozzette, M.D., Ph.D.
Jason Brenchly, Ph.D.
Dennis R. Burton, Ph.D.
Salvatore T. Butera, D.V.M., Ph.D.
Alex Carballo-Dieguez, Ph.D.
David D. Celentano, Sc.D., M.H.S.
Sarah H. Cheeseman, M.D.
David B. Clifford, M.D.
C. Budd Colby, Ph.D.
Grant Colfax, M.D.
Deborah Jean Cotton, M.D., M.P.H.
Bryan Richard Cullen, Ph.D.
Susanna Cunningham-Rundles,
Ph.D.
Richard Thomas D’Aquila, M.D.
John Delos DeLamater, Ph.D.
Roger Detels, M.D., M.S.
Carl W. Dieffenbach, Ph.D.
Daniel C. Douek, M.D., Ph.D.
D. Peter Drotman, M.D., M.P.H.
Frank Duff, M.D.
Anke A. Ehrhardt, Ph.D.
Homayoon Farzadegan, Ph.D.
Dianne M. Finkelstein, Ph.D.
Jacquelyn H. Flaskerud, Ph.D.
Gerald Herbert Friedland, M.D.
Richard Brian Gaynor, M.D.
Howard E. Gendelman, M.D.
Peter Ghazal, Ph.D
Marya Gwadz, Ph.D.
Nancy L. Haigwood, Ph.D.
Dean Hamer, Ph.D.
Polly Harrison, Ph.D.
Sharon Hillier, Ph.D.
Charles H. Hinkin, Ph.D.
Martin S. Hirsch, M.D.
David Ho, M.D.
Gary Norman Holland, M.D.
Thomas J. Hope, Ph.D.
Shiu-Lok Hu, Ph.D.
John Hylton, M.H.S., Ph.D.
David E. Kanouse, Ph.D.
Ronald C. Kennedy, Ph.D.
Vineet KewalRamani, Ph.D.
Robert Stephen Klein, M.D.
Richard Kornbluth, M.D., Ph.D.
Richard A. Koup, M.D.
Joan Kreiss, M.D., M.S.P.H.
Nathaniel R. Landau, Ph.D.
Alan L. Landay, Ph.D.
Amy Lansky, Ph.D.
Jeffrey Laurence, M.D.
Michael Lederman, M.D.
Tun-Hou Lee, D.Sc.
Michael J. Leibowitz, M.D., Ph.D.
Carol Levine, M.A.
Robert J. Levine, M.D.
Judy Lieberman, M.D., Ph.D.
H. Kim Lyerly, M.D.
David M. Margolis, M.D.
Martin H. Markowitz, M.D.
Marta L. Marthas, Ph.D.
Kenneth Hugh Mayer, M.D.
Justin C. McArthur, M.B.B.S., M.P.H.
Joseph M. McCune, M.D., Ph.D.
Ian McGowan, M.D., Ph.D.
Michael S. McGrath, M.D., Ph.D.
A.D McNaghten, Ph.D.
John Gordon McNeil, M.D., M.P.H.
Peter Messeri, Ph.D.
Donna Mildvan, M.D.
Christopher Murrill, Ph.D., M.P.H.
Jay A. Nelson, Ph.D.
Valerie Len Ng, Ph.D., M.D.
Nancy Padian, M.P.H., Ph.D.
Savita Pahwa, M.D.
Tristram G. Parslow, M.D., Ph.D.
Jeremy Paul, Ph.D.
Matija Peterlin, M.D.
Anthony John Pinching, F.R.C.P.,
D.Phil
William G. Powderly, M.D.,
F.R.A.C.P.
Lynn Pulliam, Ph.D.
Lee Ratner, M.D., Ph.D.
Andrew Rice, Ph.D.
Melissa Robbiani, Ph.D.
Yvonne J. Rosenberg, Ph.D.
Ruth M. Ruprecht, M.D., Ph.D.
Travis Sanchez, D.V.M.
Frederick A. Schmitt, Ph.D.
Gerald Schochetman, Ph.D.
Robert Turner Schooley, M.D.
Ola A. Selnes, Ph.D.
Ganes C. Sen, Ph.D.
Frederick P. Siegal, M.D.
Gail Skowron, M.D.
Whaijen Soo, M.D., Ph.D.
James L. Sorensen, Ph.D.
Leonidas Stamatatos, Ph.D.
Simon Swingler, Ph.D.
Edward Elliot Telzak, M.D.
Ernest F. Terwilliger, Ph.D.
Gwen Van Servellen, R.N., Ph.D.
Barbara Visscher, M.D., Dr.P.H.
David Vlahov, Ph.D.
David J. Volsky, Ph.D.
Bruce D. Walker, M.D.
J. Brice Weinberg, M.D.
Darrell P. Wheeler, Ph.D., M.P.H.
Steven S. Witkin, Ph.D.
Peter R. Wolfe, M.D.
Richard T. Wyatt, Ph.D.
Management group
Kevin Robert Frost
Susan J. Blumenthal, M.D., M.P.A.
Senior Policy and Medical Advisor
Deborah C. Hernan
Assistant Treasurer and Vice
President, Public Information
Rowena Johnston, Ph.D.
Vice President, Research
Jeffrey Laurence, M.D.
Senior Scientific Consultant
John F. Logan, Esq.
Assistant Secretary, Vice President,
and General Counsel
Bill Melamed
Vice President, Development
Scott Newman, M.B.A.
Assistant Treasurer and Vice
President, Finance and
Administration
Monica S. Ruiz, Ph.D., M.P.H.
Acting Director, Public Policy
A C K NO W LEDGMEN T S
amfAR extends its grateful appreciation to William H. Byer, Variable Graphics LLC, for
partial donation of the printing of this Annual Report.
PHOTO CREDITS
Page 2 Eric T. Michelson
Page 3 Lawrence Switzer
Page 6 Courtesy of Dr. Carolina Herrera; Piotr Bizior/SXC
Page 7 Courtesy of Dr. Fong Siew Moy; Lawrence Switzer
Page 8 © Les Cunliffe/Dreamstime.com
Page 10 Jeff Vespa/WireImage
Page 11 Courtesy of Dr. Ya-Lin Chiu
Page 12 Courtesy of Dr. Robin Shattock
Page 15 © Zol/Dreamstime.com
Page 16 Sam Avrett
Page 17 Courtesy of Dr. Pope Kosalaraksa
Page 19 Karl Grobl
Page 22 © Mike Rogal/Dreamstime.com; © Diadem Images/Dreamstime.com
Page 24 Lawrence Switzer
Page 25 Emily Byram
Page 26 © Dmitriy Shironosov/Dreamstime.com
Page 28 Courtesy of Dr. Peter Shalit
Page 29 Kenneth Cole Productions
Page 33 Dr. Rowena Johnston
Page 36 Courtesy of Hewlett-Packard
Page 39 Bruno
amfAR, The Foundation for AIDS Research,
is a New York State not-for-profit
corporation and is exempt from federal
income tax under Section 501(c)(3) of
the United States Internal Revenue Code
(“the code”) and corresponding New
York Revenue and Taxation Code sections.
Contributions to amfAR are tax-deductible
in accordance with the code.
amfAR meets the BBB
Page 41 Courtesy of Stanford University Archives
This Annual Report was produced by amfAR’s Public Information department:
Andrew McInnes, Group Director, Public Information
Raoul Norman, Creative Director
Constance Herndon, Senior Staff Writer
Carolyn Hanson, Staff Writer
Winnie McCroy, Staff Writer
Barbara Battle, Editorial Manager
Yolande Hunter, Production Artist
Natalie Jacobs, Assistant Coordinator
Wise Giving Alliance’s
Standards for Charity
Accountability.
AMERICAN AIRLINES is the official airline of amfAR.
T H E
A I D S
NEW YORK
F O U N D A T I O N
F O R
R E S E A R C H
120 WALL STREET, 13TH FLOOR
NEW YORK, NY 10005-3908
T: 212 806 1600
F: 212 806 1601
WASHINGTON, DC
1150 17TH STREET, NW, SUITE 406
WASHINGTON, DC 20036-4622
T: 202 331 8600
F: 202 331 8606
BANGKOK
amfAR / TREAT ASIA
EXCHANGE TOWER
21ST FLOOR, SUITE 2104
388 SUKHUMVIT ROAD, KLONGTOEY
BANGKOK 10110
THAILAND
T: +66 (0)2 663 7561
F: +66 (0)2 663 7562
w w w . a m f a r . o r g

insearchoflastingsolu tionstohiv / aids

Transcription

Similar documents

Babies born from HIV/AIDS positive mothers

amfAR Annual Events

B U CA I

Reach Out brochure - Reach Out Nkokonjeru Parish Reach Out

generationCURE Annual Events

inspiration gala los angeles

Archived Field Experiences Aarti Agarwal, HIV

PDF | 14.6mb

English - Women In Europe

Press Release - African Union